ClickCease
+1-915-850-0900 spinedoctors@gmail.com
Select Page

Functional Medicine

Back Clinic Functional Medicine Team. Functional medicine is an evolution in the practice of medicine that better addresses the healthcare needs of the 21st century. By shifting the traditional disease-centered focus of medical practice to a more patient-centered approach, functional medicine addresses the whole person, not just an isolated set of symptoms.

Practitioners spend time with their patients, listening to their histories and looking at the interactions among genetic, environmental, and lifestyle factors that can influence long-term health and complex, chronic disease. In this way, functional medicine supports the unique expression of health and vitality for each individual.

By changing the disease-centered focus of medical practice to this patient-centered approach, our physicians are able to support the healing process by viewing health and illness as part of a cycle in which all components of the human biological system interact dynamically with the environment. This process helps to seek and identify genetic, lifestyle, and environmental factors that may shift a person’s health from illness to well-being.


Boosting Energy with Hypothyroidism | Wellness Clinic

Boosting Energy with Hypothyroidism | Wellness Clinic

The cornerstone of treating hypothyroidism and reducing its symptom involves following the proper treatment. People with hypothyroidism receive the maximum relief from exhaustion when they balance their thyroid-stimulating hormone (TSH) levels, often to below 2.5 milliunits per liter (mU/L), based on study published in the Kansas Journal of Medicine.

 

“Most experts agree that after hypothyroidism is diagnosed, 1 mU/L into 3 mU/L has been an appropriate TSH range,” explains Victor Bernet, MD, an endocrinologist and assistant professor of medicine at the Mayo Clinic in Jacksonville, Fla.. However, it may take time to achieve that goal, and your symptoms, such as energy, could persist for awhile. Managing fatigue as you wait is an issue of making healthy lifestyle choices and getting enough sleep.

 

Take the Recommended Treatment

 

The good news about hypothyroidism treatment is that thyroid medication is successful for most people, especially when taken as prescribed. This means that you should follow your physician’s instructions. The most severe cases of hypothyroidism see symptoms improve with treatment within six months, states Jan Hoffman, MD, an endocrinologist and leader of the section of endocrinology at the Via Christi Clinic in Wichita, Kan.. But some individuals may continue to feel tiredness. For these individuals, Dr. Hoffman suggests medication adjustments to comprise both the T3 and T4 hormones. This is not yet a mainstream treatment, if you haven’t been getting good results from your present drug 35, about trying it, but you might talk to your primary care doctor or endocrinologist.

 

Balance Your Diet

 

Eating a nutritious diet rich in fruits and vegetables, whole grains, and proteins can help give you. Cut back on added sugars, which can increase the fatigue you are feeling out of migraines. “There is certainly an advantage to maintaining a wholesome, well-balanced diet with regular exercise to improve health generally,” Hoffman says. Because sleep quality can be reduced by this, additionally you may need to avoid eating large meals within a few hours of bedtime. Instead, opt for a dinner and a snack before bed.

 

Try Cognitive Behavioral Therapy

 

Cognitive behavioral therapy (CBT) is a style of therapy that helps you to change negative thought patterns and replace them with more positive ones. In studies looking at physical action, CBT, and fatigue, researchers have observed that this kind of therapy appears to help people feel like they’re more active or capable of being active, and so less fatigued, even if they aren’t really increasing their physical activity levels. This is in part as counter the belief that you’re simply tired from the consequences of hypothyroidism to do anything and one tactic of CBT is to assist you.

 

Limit Alcohol and Caffeine

 

If you’re fighting fatigue from hypothyroidism, it’s easy to slip into a cycle of drinking lots of drinks during the day and then using a nightcap to bring you back down. It will not tackle fatigue although caffeine can occasionally give you a elevator, such as feeling perkier in the morning. What’s worse, this cycle of caffeine and alcohol to wind down could be sapping your energy over and beyond the fatigue. Both caffeine and alcohol interfere with your body’s ability to achieve sleep. Cut back on carbonated beverages, adhering before noon, and have one alcoholic beverage if any, in the day.

 

Engage in Physical Activity

 

You may believe eczema has left you but physical activity, even a little at a time, can help counter fatigue, enhance your energy levels also improve your sleep quality. Try for the national recommendations for physical activity that is healthy: being active for at least 30 minutes. Exercising in the evening can make it difficult to get to sleep later try to schedule your workouts for earlier in the day.

 

Take Steps to Sleep More Soundly

 

Obtaining enough high-quality sleep people need seven can help fight fatigue. Deep sleep requires the appropriate “stage”: A slightly cool, dark, sound-free site. To get your body to the sleep rhythm, set a regular time to go to wake up and to sleepon weekends and holidays. If you’ve taken these measures to boost your sleep however are still lacking energy during the day and suspect you are not sleeping well, think about a sleep evaluation to determine if you have some sleeping disorders, such as sleep apnea, that may be robbing you of a good night’s sleep.

 

Stop Smoking

 

Nicotine is a stimulant. So even though smoking can feel as a relaxing routine, it’s interfering with your sleep quality and, in turn, adding to fatigue. Individuals who stop smoking find that once they’ve made it during the withdrawal period, they’ve sleep and more energy. Smoking is known to contribute to autoimmune disease, which might be challenging your hypothyroidism treatment plan’s development. Take note that hypothyroidism can be also complicated by smoking cessation, so be certain you quit smoking under the supervision of your doctor.

 

Get Routine Medical Tests

 

Dr. Bernet contrasts thyroid function into a well-functioning vehicle. “If your car is acting up and your oil is low or you have not changed it in awhile, you need oil,” he says. This is the equivalent of taking medication to get your thyroid hormone levels back to normal. This, too, applies to sleeplessness therapy. If your thyroid screening indicates you are at normal levels after treatment but you are still feeling exhausted, ask for further evaluation. About one in five people experience fatigue, but hypothyroidism is simply one cause of exhaustion that is ongoing.

 

The scope of our information is limited to chiropractic and spinal injuries and conditions. To discuss options on the subject matter, please feel free to ask Dr. Jimenez or contact us at 915-850-0900 .�
 

By Dr. Alex Jimenez

 

Additional Topics: Wellness

 

Overall health and wellness are essential towards maintaining the proper mental and physical balance in the body. From eating a balanced nutrition as well as exercising and participating in physical activities, to sleeping a healthy amount of time on a regular basis, following the best health and wellness tips can ultimately help maintain overall well-being. Eating plenty of fruits and vegetables can go a long way towards helping people become healthy.

 

blog picture of cartoon paperboy big news

 

TRENDING TOPIC: EXTRA EXTRA: About Chiropractic

 

 

About Thyroid Disease and Fatigue | Wellness Clinic

About Thyroid Disease and Fatigue | Wellness Clinic

Are you tired of being tired? Whatever you call it, exhaustion, fatigue, lethargy, or feeling run down, overtired, or just plainly pooped out, fatigue is a frequent symptom associated with thyroid disease.

 

How does thyroid disease cause fatigue?

 

We’re not talking about regular fatigue after a late night. This is a debilitating fatigue. You might find yourself needing a rest in the afternoon to endure until dinnertime. Or you wake up tired and still sleep ten to twelve hours a night. Or you’re less able to work out, and your endurance is reduced because you are weak and lethargic. Or brain-fogged and exhausted out may just walk around about exactly the quantity of sleep that used to make you feeling refreshed.

 

There are a number of important things to know about the connections between thyroid disease and fatigue, and ten of the most significant things to know about boosting your energy and battling fatigue are mentioned below.

 

Fatigue and Hypothyroidism

 

Fatigue is a really common symptom of hypothyroidism, an underactive or reduced thyroid function, in many individuals. Many patients report that their fatigue is diminished or even completely solved after the treatment for hypothyroidism is optimized. Various treatment approaches, including functional medicine can help improve hypothyroidism.

 

Fatigue and Hyperthyroidism

 

Fatigue is also a symptom of hyperthyroidism, an overactive or increased thyroid function, in some patients. Exhaustion is present even when you have gotten an adequate quantity of sleep. In other scenarios, exhaustion or fatigue associated with hyperthyroidism may result from insomnia, anxiety, or disrupted sleep patterns. Typically, treatment for hyperthyroidism can help resolve the patient’s overall symptoms.

 

Autoimmune Thyroid Disease and Fatigue

 

Even when thyroid function tests demonstrate that the thyroid gland is “normal” and hormone levels fall within the benchmark range, the existence of elevated thyroid antibodies, which may indicate autoimmune Hashimoto’s disease or Graves’ disease, may lead to fatigue as a symptom in some patients.

 

Dietary Changes

 

Some thyroid patients, including individuals who don’t have celiac disease or gluten intolerance, have reported a decrease in fatigue when they switch into a gluten-free diet plan. A gluten-free diet is a nutrition plan free of wheat and gluten products. Others have reported similar effects by removing sugar, dairy, or other foods in the diet.

 

Unrefreshing Sleep

 

Some people experience fatigue due to what is called unrefreshing sleep. This indicates that you’ve had enough sleep seven or more hours, but you wake up and feel tired, because the sleep has been of poor quality, interrupted, or did not reach levels that are restorative. Unrefreshing sleep could be associated with dysfunction, in addition to chronic fatigue syndrome and fibromyalgia in most cases.

 

Iron

 

Some thyroid patients suffering from fatigue may be reduced in iron, in particular, the saved form of iron known as ferritin. It is worth having ferritin levels assessed by your healthcare professional, and if they are not optimal (in the upper end of the reference range), talk with your doctor about supplementing with iron, or even incorporating more iron to your diet through foods. An excess of iron, in particular, a hereditary condition called hemochromatosis, may also be related to fatigue. There is a link between thyroid conditions and an increased probability of hemochromatosis.

 

Chronic Fatigue Syndrome and Fibromyalgia

 

In case you have long-term, debilitating fatigue, and the tiredness is accompanied by other symptoms like enlarged lymph nodes, a chronic sore throat, and/or body/muscle aches pains, you may have other conditions such as chronic fatigue syndrome and/or fibromyalgia. These conditions are common in thyroid patients than in the general populace.

 

T3 and Natural Thyroid

 

Some thyroid patients on thyroid hormone replacement have reported a rise in their exhaustion levels or fatigue when switching from a T4 only treatment (i.e., levothyroxine), to some T4/T3 treatment, for example, the inclusion of artificial T3, or use of a natural desiccated thyroid medication.

 

Sleep Apnea

 

Thyroid patients are at greater risk of sleep apnea, and at which breathing stops for short periods during sleep. Sleep apnea can contribute to fatigue, due to an improper oxygen intake when sleeping. Thyroid patients experiencing fatigue should speak with a healthcare professional about having a sleep study or evaluation completed to determine if sleep abnormalities, such as apnea, may be contributing to the fatigue.

 

Get Better and More Sleep

 

Be sure you receive optimum treatment for your thyroid illness and address any sleeping disorders, food sensitivities, and imbalances on your iron levels. Also, make sure you get adequate sleep. According to the National Sleep Foundation, many adults need a minimum of seven to eight hours each night, and a considerable proportion of us aren’t currently getting this level of sleep on a regular basis.

 

Here are some tips to help avoid fatigue by getting better and more sleep:

 

  • Try to maintain the same sleep schedule weekdays and weekends
  • Keep your bedroom cool
  • Don’t watch television or work in your bedroom
  • Avoid alcohol and caffeine in the day, and before bedtime
  • Don’t take naps
  • Don’t exercise after dinner period
  • Have a hot shower or bath before bedtime
  • Use a sound conditioner or earplugs to block noise
  • Avoid large meals before bedtime
  • Boost light exposure during the day
  • Minimize lighting into your bedroom by using blinds or blackout curtains, turn off tv and computer at night, prevent illuminated clocks, and don’t read from or look at backlit devices or smart phones at nighttime
  • Listen to relaxation or guided imagery audios to help fall asleep.
  • Do not drink too much liquid in the evening
  • Restrict changes in your job shifts
  • Drink a natural or relaxation tea at bedtime
  • Have a bedtime snack with protein

 

The scope of our information is limited to chiropractic and spinal injuries and conditions. To discuss options on the subject matter, please feel free to ask Dr. Jimenez or contact us at 915-850-0900 .�
 

By Dr. Alex Jimenez

 

Additional Topics: Wellness

 

Overall health and wellness are essential towards maintaining the proper mental and physical balance in the body. From eating a balanced nutrition as well as exercising and participating in physical activities, to sleeping a healthy amount of time on a regular basis, following the best health and wellness tips can ultimately help maintain overall well-being. Eating plenty of fruits and vegetables can go a long way towards helping people become healthy.

 

blog picture of cartoon paperboy big news

 

TRENDING TOPIC: EXTRA EXTRA: About Chiropractic

 

 

Three Metabolic Energy Systems

Three Metabolic Energy Systems

Personal Training 101

energy personal trainer

How You Get Energy & How You Use It

energy asparagus eggs tomatos We usually talk of energy in general terms, as in �I don�t have a lot of energy today� or �You can feel the energy in the room.� But what really is energy? Where do we get the energy to move? How do we use it? How do we get more of it? Ultimately, what controls our movements? The three metabolic energy pathways are the�phosphagen system, glycolysis�and the�aerobic system.�How do they work, and what is their effect?

Albert Einstein, in his infinite wisdom, discovered that the total energy of an object is equal to the mass of the object multiplied by the square of the speed of light. His formula for atomic energy, E = mc2, has become the most recognized mathematical formula in the world. According to his equation, any change in the energy of an object causes a change in the mass of that object. The change in energy can come in many forms, including mechanical, thermal, electromagnetic, chemical, electrical or nuclear. Energy is all around us. The lights in your home, a microwave, a telephone, the sun; all transmit energy. Even though the solar energy that heats the earth is quite different from the energy used to run up a hill, energy, as the first law of thermodynamics tells us, can be neither created nor destroyed. It is simply changed from one form to another.

ATP Re-Synthesis

energyThe energy for all physical activity comes from the conversion of high-energy phosphates (adenosine�triphosphate�ATP) to lower-energy phosphates (adenosine�diphosphate�ADP; adenosine�monophosphate�AMP; and inorganic phosphate, Pi). During this breakdown (hydrolysis) of ATP, which is a water-requiring process, a proton, energy and heat are produced: ATP + H2O ��ADP + Pi�+ H+�+ energy + heat. Since our muscles don�t store much ATP, we must constantly resynthesize it. The hydrolysis and resynthesis of ATP is thus a circular process�ATP is hydrolyzed into ADP and Pi, and then ADP and Pi�combine to resynthesize ATP. Alternatively, two ADP molecules can combine to produce ATP and AMP: ADP + ADP ��ATP + AMP.

Like many other animals, humans produce ATP through three metabolic pathways that consist of many enzyme-catalyzed chemical reactions: the phosphagen system, glycolysis and the aerobic system. Which pathway your clients use for the primary production of ATP depends on how quickly they need it and how much of it they need. Lifting heavy weights, for instance, requires energy much more quickly than jogging on the treadmill, necessitating the reliance on different energy systems. However, the production of ATP is never achieved by the exclusive use of one energy system, but rather by the coordinated response of all energy systems contributing to different degrees.

1. Phosphagen System

energy woman sit-ups on machineDuring short-term, intense activities, a large amount of power needs to be produced by the muscles, creating a high demand for ATP. The phosphagen system (also called the ATP-CP system) is the quickest way to resynthesize ATP (Robergs & Roberts 1997). Creatine phosphate (CP), which is stored in skeletal muscles, donates a phosphate to ADP to produce ATP: ADP + CP ��ATP + C. No carbohydrate or fat is used in this process; the regeneration of ATP comes solely from stored CP. Since this process does not need oxygen to resynthesize ATP, it is anaerobic, or oxygen-independent. As the fastest way to resynthesize ATP, the phosphagen system is the predominant energy system used for all-out exercise lasting up to about 10 seconds. However, since there is a limited amount of stored CP and ATP in skeletal muscles, fatigue occurs rapidly.

2. Glycolysis

energyGlycolysis is the predominant energy system used for all-out exercise lasting from 30 seconds to about 2 minutes and is the second-fastest way to resynthesize ATP. During glycolysis, carbohydrate�in the form of either blood glucose (sugar) or muscle glycogen (the stored form of glucose)�is broken down through a series of chemical reactions to form pyruvate (glycogen is first broken down into glucose through a process called�glycogenolysis). For every molecule of glucose broken down to pyruvate through glycolysis, two molecules of usable ATP are produced (Brooks et al. 2000). Thus, very little energy is produced through this pathway, but the trade-off is that you get the energy quickly. Once pyruvate is formed, it has two fates: conversion to lactate or conversion to a metabolic intermediary molecule called acetyl coenzyme A (acetyl-CoA), which enters the mitochondria for oxidation and the production of more ATP (Robergs & Roberts 1997). Conversion to lactate occurs when the demand for oxygen is greater than the supply (i.e., during anaerobic exercise). Conversely, when there is enough oxygen available to meet the muscles� needs (i.e., during aerobic exercise), pyruvate (via acetyl-CoA) enters the mitochondria and goes through aerobic metabolism.

When oxygen is not supplied fast enough to meet the muscles� needs (anaerobic glycolysis), there is an increase in hydrogen ions (which causes the muscle pH to decrease; a condition called acidosis) and other metabolites (ADP, Pi�and potassium ions). Acidosis and the accumulation of these other metabolites cause a number of problems inside the muscles, including inhibition of specific enzymes involved in metabolism and muscle contraction, inhibition of the release of calcium (the trigger for muscle contraction) from its storage site in muscles, and interference with the muscles� electrical charges (Enoka & Stuart 1992; Glaister 2005; McLester 1997). As a result of these changes, muscles lose their ability to contract effectively, and muscle force production and exercise intensity ultimately decrease.

3. Aerobic System

energySince humans evolved for aerobic activities (Hochachka, Gunga & Kirsch 1998; Hochachka & Monge 2000), it�s not surprising that the aerobic system, which is dependent on oxygen, is the most complex of the three energy systems. The metabolic reactions that take place in the presence of oxygen are responsible for most of the cellular energy produced by the body. However, aerobic metabolism is the slowest way to resynthesize ATP. Oxygen, as the patriarch of metabolism, knows that it is worth the wait, as it controls the fate of endurance and is the sustenance of life. �I�m oxygen,� it says to the muscle, with more than a hint of superiority. �I can give you a lot of ATP, but you will have to wait for it.�

The aerobic system�which includes the�Krebs cycle�(also called the�citric acid cycle or TCA cycle) and the�electron transport chain�uses blood glucose, glycogen and fat as fuels to resynthesize ATP in the mitochondria of muscle cells (see the sidebar �Energy System Characteristics�). Given its location, the aerobic system is also called�mitochondrial respiration.�When using carbohydrate, glucose and glycogen are first metabolized through glycolysis, with the resulting pyruvate used to form acetyl-CoA, which enters the Krebs cycle. The electrons produced in the Krebs cycle are then transported through the electron transport chain, where ATP and water are produced (a process called�oxidative phosphorylation) (Robergs & Roberts 1997). Complete oxidation of glucose via glycolysis, the Krebs cycle and the electron transport chain produces 36 molecules of ATP for every molecule of glucose broken down (Robergs & Roberts 1997). Thus, the aerobic system produces 18 times more ATP than does anaerobic glycolysis from each glucose molecule.

energyFat, which is stored as triglyceride in adipose tissue underneath the skin and within skeletal muscles (called�intramuscular triglyceride), is the other major fuel for the aerobic system, and is the largest store of energy in the body. When using fat, triglycerides are first broken down into free fatty acids and glycerol (a process called�lipolysis). The free fatty acids, which are composed of a long chain of carbon atoms, are transported to the muscle mitochondria, where the carbon atoms are used to produce acetyl-CoA (a process called�beta-oxidation).

Following acetyl-CoA formation, fat metabolism is identical to carbohydrate metabolism, with acetyl-CoA entering the Krebs cycle and the electrons being transported to the electron transport chain to form ATP and water. The oxidation of free fatty acids yields many more ATP molecules than the oxidation of glucose or glycogen. For example, the oxidation of the fatty acid palmitate produces 129 molecules of ATP (Brooks et al. 2000). No wonder clients can sustain an aerobic activity longer than an anaerobic one!

Understanding how energy is produced for physical activity is important when it comes to programming exercise at the proper intensity and duration for your clients. So the next time your clients get done with a workout and think, �I have a lot of energy,� you�ll know exactly where they got it.

Energy System Characteristics
energy

Energy System Workouts

Have clients warm up and cool down before and after each workout.

Phosphagen System

An effective workout for this system is short, very fast sprints on the treadmill or bike lasting 5�15 seconds with 3�5 minutes of rest between each. The long rest periods allow for complete replenishment of creatine phosphate in the muscles so it can be reused for the next interval.

  • 2 sets of 8 x 5 seconds at close to top speed with 3:00 passive rest and 5:00 rest between sets
  • 5 x 10 seconds at close to top speed with 3:00�4:00 passive rest

Glycolysis

This system can be trained using fast intervals lasting 30 seconds to 2 minutes with an active-recovery period twice as long as the work period (1:2 work-to-rest ratio).

  • 8�10 x 30 seconds fast with 1:00 active recovery
  • 4 x 1:30 fast with 3:00 active recovery

Aerobic System

While the phosphagen system and glycolysis are best trained with intervals, because those metabolic systems are emphasized only during high-intensity activities, the aerobic system can be trained with both continuous exercise and intervals.

  • 60 minutes at 70%�75% maximum heart rate
  • 15- to 20-minute tempo workout at lactate threshold intensity (about 80%�85% maximum heart rate)
  • 5 x 3:00 at 95%�100% maximum heart rate with 3:00 active recovery

by�Jason Karp, PhD

read more button

References:

Brooks, G.A., et al. 2000.�Exercise Physiology: Human Bioenergetics and Its Applications.Mountain View, CA: Mayfield.

Enoka, R.M., & Stuart, D.G. 1992. Neurobiology of muscle fatigue.�Journal of Applied Physiology, 72�(5), 1631�48.

Glaister, M. 2005. Multiple sprint work: Physiological responses, mechanisms of fatigue and the influence of aerobic fitness.�Sports Medicine, 35�(9), 757�77.

Hochachka, P.W., Gunga, H.C., & Kirsch, K. 1998. Our ancestral physiological phenotype: An adaptation for hypoxia tolerance and for endurance performance?�Proceedings of the National Academy of Sciences, 95,�1915�20.

Hochachka, P.W., & Monge, C. 2000. Evolution of human hypoxia tolerance physiology.�Advances in Experimental and Medical Biology, 475,�25�43.

McLester, J.R. 1997. Muscle contraction and fatigue: The role of adenosine 5′-diphosphate and inorganic phosphate.�Sports Medicine, 23�(5), 287�305.

Robergs, R.A. & Roberts, S.O. 1997.�Exercise Physiology: Exercise, Performance, and Clinical Applications.�Boston: William C. Brown.

Dietary Strategies: Treatment Of Metabolic Syndrome

Dietary Strategies: Treatment Of Metabolic Syndrome

Dietary Strategies:

Abstract: Metabolic syndrome (MetS) is established as the combination of central obesity and different metabolic disturbances, such as insulin resistance, hypertension and dyslipidemia. This cluster of factors affects approximately 10%�50% of adults worldwide and the prevalence has been increasing in epidemic proportions over the last years. Thus, dietary strategies to treat this heterogenic disease are under continuous study. In this sense, diets based on negative-energy-balance, the Mediterranean dietary pattern, n-3 fatty acids, total antioxidant capacity and meal frequency have been suggested as effective approaches to treat MetS. Furthermore, the type and percentage of carbohydrates, the glycemic index or glycemic load, and dietary fiber content are some of the most relevant aspects related to insulin resistance and impaired glucose tolerance, which are important co-morbidities of MetS. Finally, new studies focused on the molecular action of specific nutritional bioactive compounds with positive effects on the MetS are currently an objective of scientific research worldwide. The present review summarizes some of the most relevant dietary approaches and bioactive compounds employed in the treatment of the MetS to date.

Keywords: metabolic syndrome; dietary strategies; bioactive compounds

1. Metabolic Syndrome

dietary healthy unhealthy foodIt was during the period between 1910 and 1920 when it was suggested for the first time that a cluster of associated metabolic disturbances tended to coexist together [1]. Since then, different health organisms have suggested diverse definitions for metabolic syndrome (MetS) but there has not yet been a well-established consensus. The most common definitions are summarized in Table 1. What is clear for all of these is that the MetS is a clinical entity of substantial heterogeneity, commonly represented by the combination of obesity (especially abdominal obesity), hyperglycemia, dyslipidemia and/or hypertension [2�6].

dietary table 1

Obesity consists of an abnormal or excessive fat accumulation, for which the main cause is a chronic imbalance between energy intake and energy expenditure [7,8]. The excess of energy consumed is primarily deposited in the adipose tissue as triglycerides (TG) [9].

Dyslipidemia encompasses elevated serum TG levels, increased low density lipoprotein- cholesterol (LDL-c) particles, and reduced levels of high density lipoprotein-cholesterol (HDL-c) [10]. It is associated with hepatic steatosis [11], dysfunction of pancreatic ?-cells [12] and elevated risk of atherosclerosis [13], among others.

Another main modifiable MetS manifestation is hypertension, which is mainly defined as a resting systolic blood pressure (SBP) ? 140 mmHg or diastolic blood pressure (DBP) ? 90 mmHg or drug prescription to lower hypertension [14]. It usually involves narrowed arteries and is identified as a major cardiovascular and renal risk factor, related to heart and vascular disease, stroke and myocardial infarction [13,15�17].

Hyperglycemia, related insulin resistance and type 2 diabetes mellitus are characterized by an impaired uptake of glucose by the cells, that lead to elevated plasma glucose levels, glycosuria and ketoacidosis [18]. It is responsible for different tissue damage that shortens the life expectancy of diabetics, involving cardiovascular diseases (CVD), atherosclerosis, hypertension [19], ?-cell dysfunction [12], kidney disease [20] or blindness [21]. Currently, diabetes is considered the leading cause of death in developed countries [22].

Moreover, oxidative stress and low grade inflammation are two important mechanisms implicated in the etiology, pathogenesis, and development of MetS [23]. Oxidative stress is defined as an imbalance between the pro-oxidants and antioxidants in the body [24]. It plays a key role in the development of atherosclerosis by different mechanisms such as the oxidation of LDL-c particles [25] or impairment of HDL-c functions [26]. Inflammation is an immune system response to injury hypothesized to be a major mechanism in the pathogenesis and progression of obesity related disorders and the link between adiposity, insulin resistance, MetS and CVD [27].

Although the prevalence of the MetS varies broadly around the word and depends on the source used for its definition, it is clear that over the last 40�50 years the number of people presenting with this syndrome has risen in epidemic proportions [28]. Moreover, the frequency of this syndrome is increased in developed countries, sedentary people, smokers, low socioeconomic status population, as well as in individuals with unhealthy dietary habits [29,30].

For all of this, there is currently a wide concern to find effective strategies to detect, treat and control the comorbidities associated with MetS. This is a complex challenge as MetS is a clinical entity of substantial heterogeneity and therefore, the different cornerstones implicated in its development should be addressed. In this review we compiled and examined different dietary patterns and bioactive compounds that have pointed out to be effective in MetS treatment.

2. Dietary Patterns

dietarySeveral dietary strategies and their potential positive effects on the prevention and treatment of the different metabolic complications associated to the MetS, are described below and summarized in Table 2.

dietary table 22.1. Energy-Restricted Diet Strategies

dietary

Energy restricted diets are probably the most commonly used and studied dietary strategies for combating excess weight and related comorbidities. They consist in personalized regimes that supply less calories than the total energy expended by a specific individual [31].

A hypocaloric diet results in a negative energy balance and subsequently, in body weight reduction [31]. Weight loss is achieved via fat mobilization from different body compartments as a consequence of the lipolysis process necessary to provide energy substrate [32,33]. In people who are overweight or suffering from obesity, as is the case of most people with MetS, weight loss is important as it is associated with improvement of related disorders such as abdominal obesity (visceral adipose tissue), type 2 diabetes, CVD or inflammation [32�36].

Moreover, as described above, low grade inflammation is associated with MetS and obesity. Therefore, of particular importance is the fact that in obese individuals following a hypocaloric diet, a depletion of plasma inflammatory markers such as interleukin (IL)-6 has been observed [34]. Thus, caloric restriction in obese people suffering MetS may improve the whole-body pro-inflammatory state.

At the same time, body weight reduction is associated with improvements in cellular insulin signal transduction, increments in peripheral insulin sensitivity and higher robustness in insulin secretory responses [32,36]. People with excess body weight who are at risk of developing type 2 diabetes, may benefit from a hypocaloric regime by improving plasma glucose levels and insulin resistance.

In addition, different intervention trials have reported a relationship between energy restricted diets and lower risk of developing CVD. In this sense, in studies with obese people following a hypocaloric diet, improvements in lipid profile variables such as reductions of LDL-c and plasma�TG levels, as well as improvements in hypertension via depletion of SBP and DBP levels have been observed [35,37].

Among the different nutritional intervention trials, a reduction of 500�600 kcal a day of the energy requirements is a well-established hypocaloric dietary strategy, which has demonstrated to be effective in weight reduction [38,39]. However, the challenge lies in maintaining the weight loss over time, as many subjects can follow a prescribed diet for a few months, but most people have difficulty in maintaining the acquired habits over the long term [40,41].

2.2. Diets Rich in Omega-3 Fatty Acids

dietary foods omega 3 infographicThe very long-chain eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are essential omega-3 polyunsaturated fatty acids (n-3 PUFAs) for human physiology. Their main dietary sources are fish and algal oils and fatty fish, but they can also be synthesized by humans from ?-linolenic acid [40].

There is a moderate body of evidence suggesting that n-3 PUFAs, mainly EPA and DHA, have a positive role in the prevention and treatment of the pathologies associated to MetS [42].

In this context, it has been described that EPA and DHA have the ability to reduce the risk of developing CVD and cardiometabolic abnormalities as well as CVD-related mortality [42]. These beneficial effects are thought to be mainly due to the ability of these essential fatty acids to reduce plasma TG levels [43].

Moreover, different studies have shown that people following an increased n-3 PUFA diet have reduced plasma levels of the pro-inflammatory cytokines IL-6 and tumor necrosis factor-alpha (TNF?), as well as plasma C-reactive protein (CRP) [44]. These effects are probably mediated by resolvins, maresins and protectins, which are EPA and DHA metabolic products with anti-inflammatory properties [44].

There are some studies that have observed an association between n-3 ingestion and improvements or prevention of type 2 diabetes development. However, other studies found opposite results [44]. Thus, it cannot be made any specific affirmation in this respect.

The European Food Safety Authority recommends and intake of 250 mg EPA + DHA a day, in the general healthy population as a primary prevention of CVD [45]. These amounts can be achieved with an ingestion of 1�2 fatty fish meals per week [45].

2.3. Diets Based on Low Glycemic Index/Load

dietary salad unconstructedOver the last ten years, the concern about the quality of the carbohydrates (CHO) consumed has risen [46]. In this context, the glycemic index (GI) is used as a CHO quality measure. It consists in a ranking on a scale from 0 to 100 that classifies carbohydrate-containing foods according to the postprandial glucose response [47]. The higher the index, the more promptly the postprandial serum glucose rises and the more rapid the insulin response. A quick insulin response leads to rapid hypoglycemia, which is suggested to be associated with an increment of the feeling of hunger and to a subsequent higher caloric intake [47]. The glycemic load (GL) is equal to the GI multiplied by the number of grams of CHO in a serving [48].

There is a theory which states that MetS is a consequence of an elevated intake of high GI foods over time, among others unhealthy dietary habits [49]. In this sense, following a diet rich in high GI CHO has been associated with hyperglycemia, insulin resistance, type 2 diabetes, hypertriglyceridemia, CVD, and obesity [47,50,51], abnormalities directly related to MetS.

On the contrary, a low GI diet has been associated with slower absorption of the CHO and subsequently smaller blood glucose fluctuations, which indicate better glycemic control [46]. In patients with type 2 diabetes, diets based on low GI are associated with reductions in glycated hemoglobin (HbA1c) and fructosamine blood levels, two biomarkers used as key monitoring factors in diabetes management [52,53].

For all of this, it is common to find the limitation of CHO at high GI among the advice for MetS treatment [28], in particular with respect to �ready-to-eat processed foods� including sweetened beverages, soft drinks, cookies, cakes, candy, juice drinks, and other foods which contain high amounts of added sugars [54].

2.4. Diets with High Total Antioxidant Capacity

dietary antioxidant foodsDietary total antioxidant capacity (TAC) is an indicator of diet quality defined as the sum of antioxidant activities of the pool of antioxidants present in a food [55]. These antioxidants have the capacity to act as scavengers of free radicals and other reactive species produced in the organisms [56]. Taking into account that oxidative stress is one of the remarkable unfortunate physiological states of MetS, dietary antioxidants are of main interest in the prevention and treatment of this multifactorial disorder [57]. Accordingly, it is well-accepted that diets with a high content of spices, herbs, fruits, vegetables, nuts and chocolate, are associated with a decreased risk of oxidative stress-related diseases development [58�60]. Moreover, several studies have analyzed the effects of dietary TAC in individuals suffering from MetS or related diseases [61,62]. In the Tehran Lipid and Glucose Study it was demonstrated that a high TAC has beneficial effects on metabolic disorders and especially prevents weight and abdominal fat gain [61]. In the same line, research conducted in our institutions also evidenced that beneficial effects on body weight, oxidative stress biomarkers and other MetS features were positively related with higher TAC consumption in patients suffering from MetS [63�65].

In this sense, the World Health Organization (WHO) recommendation for fruit and vegetables consumption (high TAC foods) for the general population is a minimum of 400 g a day [66]. Moreover, cooking with spices is recommended in order to increase the TAC dietary intake and, at the same time, maintain flavor while reducing salt [67].

2.5. Moderate-High Protein Diets

dietary Protein rich FoodsThe macronutrient distribution set in a weight loss dietary plan has commonly been 50%�55% total caloric value from CHO, 15% from proteins and 30% from lipids [57,68]. However, as most people have difficulty in maintaining weight loss achievements over time [69,70], research on increment of protein intake (>20%) at the expense of CHO was carried out [71�77].

Two mechanisms have been proposed to explain the potential beneficial effects of high-moderate protein diets: the increment of diet-induced thermogenesis [73] and the increase of satiety [78]. The increment of the thermogenesis is explained by the synthesis of peptide bonds, production of urea and gluconeogenesis, which are processes with a higher energy requirement than the metabolism of lipids or CHO [75]. An increment of different appetite-control hormones such as insulin, cholecystokinin or glucagon-like peptide 1, may clarify the satiety effect [79].

Other beneficial effects attributed to moderate-high protein diets in the literature are the improvement of glucose homeostasis [80], the possibility of lower blood lipids [81], the reduction of blood pressure [82], the preservation of lean body mass [83] or the lower of cardiometabolic disease risk [84,85]. However, there are other studies that have not found benefits associated to a moderate-high protein diet [76]. This fact may be explained by the different type of proteins and their amino acid composition [80], as well as by the different type of populations included in each study [85]. Therefore, more research in the field is needed in order to make these results consistent.

In any case, when a hypocaloric diet is implemented, it is necessary to slightly increase the amount of proteins. Otherwise it would be difficult to reach the protein energy requirements, established as 0.83 g/kg/day for isocaloric diets and which should probably be at least 1 g/kg/day for energy-restricted diets [86].

2.6. High Meal Frequency Pattern

dietary eating time

The pattern of increasing meal frequency in weight loss and weight control interventions has currently become popular among professionals [87,88]. The idea is to distribute the total daily energy�intake into more frequently and smaller meals. However, there is no strong evidence about the efficacy of this habit yet [89]. While some investigations have found an inverse association between the increment of meals per day and body weight, body mass index (BMI), fat mass percentage or metabolic diseases such as coronary heart disease or type 2 diabetes [71,88,90�92], others have found no association [93�95].

Different mechanisms by which high meal frequency can have a positive effect on weight and metabolism management have been proposed. An increment of energy expenditure was hypothesized; however, the studies carried out in this line have concluded that total energy expenditure does not differ among different meal frequencies [96,97]. Another postulated hypothesis is that the greater the number of meals a day, the higher the fat oxidation, but again no consensus has been achieved [89,98]. An additional suggested mechanism is that increasing meal frequency leads to plasma glucose levels with lower oscillations and reduced insulin secretion which is thought to contribute to a better appetite control. However, these associations have been found in population with overweight or high glucose levels but in normal-weight or normoglycaemic individuals the results are still inconsistent [93,99�101].

2.7. The Mediterranean Diet

dietary Mediterranean DietThe concept of the Mediterranean Diet (MedDiet) was for the first time defined by the scientific Ancel Keys who observed that those countries around the Mediterranean Sea, which had a characteristic diet, had less risk of suffering coronary heart diseases [102,103].

The traditional MedDiet is characterized by a high intake of extra-virgin olive oil and plant foods (fruits, vegetables, cereals, whole grains, legumes, tree nuts, seeds and olives), low intakes of sweets and red meat and moderate consumption of dairy products, fish and red wine [104].

There is a lot of literature supporting the general health benefits of the MedDiet. In this sense, it has been reported that a high adherence to this dietary pattern protects against mortality and morbidity from several causes [105]. Thus, different studies suggested the MedDiet as a successful tool for the prevention and treatment of MetS and related comorbidities [106�108]. Moreover, recent meta-analysis concluded that the MedDiet is associated with less risk of developing type 2 diabetes and with a better glycemic control in people with this metabolic disorder [107,109,110]. Other studies have found a positive correlation between the adherence to a MedDiet pattern and reduced risk of developing CVD [111�114]. In fact, many studies have found a positive association between following a MedDiet and improvements in lipid profile by reduction of total cholesterol, LDL-c and TG, and an increase in HDL-c [111�115]. Finally, different studies also suggest that the MedDiet pattern may be a good strategy for obesity treatment as it has been associated with significant reductions in body weight and waist circumference [108,116,117].

The high amount of fiber which, among other beneficial effects, helps to weight control providing satiety; and the high antioxidants and anti-inflammatory nutrients such as n-3 fatty acids, oleic acid or phenolic compounds, are thought to be the main contributors to the positive effects attributed to the MedDiet [118].

For all these reasons, efforts to maintain the MedDiet pattern in Mediterranean countries and to implement this dietary habits in westernized countries with unhealthy nutritional patterns should be made.

3. Dietary: Single Nutrients and Bioactive Compounds

dietary Nutrition single nutrientNew studies focused on the molecular action of nutritional bioactive compounds with positive effects on MetS are currently an objective of scientific research worldwide with the aim of designing more personalized strategies in the framework of molecular nutrition. Among them, flavonoids and antioxidant vitamins are some of the most studied compounds with different potential benefits such as antioxidant, vasodilatory, anti-atherogenic, antithrombotic, and anti-inflammatory effects [119]. Table 3 summarizes different nutritional bioactive compounds with potential positive effects on MetS, including the possible molecular mechanism of action involved.

dietary table 3

3.1. Ascorbate

dietary AscorbateVitamin C, ascorbic acid or ascorbate is an essential nutrient as human beings cannot synthesize it. It is a water-soluble antioxidant mainly found in fruits, especially citrus (lemon, orange), and vegetables (pepper, kale) [120]. Several beneficial effects have been associated to this vitamin such as antioxidant and anti-inflammatory properties and prevention or treatment of CVD and type 2 diabetes [121�123].

This dietary component produces its antioxidant effect primarily by quenching damaging free radicals and other reactive oxygen and nitrogen species and therefore preventing molecules such as LDL-c from oxidation [122]. It can also regenerate other oxidized antioxidants like tocopherol [124].

Moreover, it has been described that ascorbic acid may reduce inflammation as it is associated with depletion of CRP levels [125]. This is an important outcome to take in consideration in the treatment of MetS sufferers, as they usually present low grade inflammation [27].

Supplementation with vitamin C have also been associated with prevention of CVD by improving the endothelial function [126] and probably by lowering blood pressure [121]. These effects are thought to be exerted by the ability of vitamin C to enhance the endothelial nitric oxide synthase enzyme (eNOS) activity and to reduce HDL-c glycation [127].

Additionally, several studies have attributed to ascorbate supplementation an antidiabetic effect by improving whole body insulin sensitivity and glucose control in people with type 2 diabetes [123]. These antidiabetic properties are thought to be mediated by optimization of the insulin secretory function of the pancreatic islet cells by increasing muscle sodium-dependent vitamin C transporters (SVCTs) [128].

Despite all of this, it should be taken into account that most people reach ascorbic acid requirements (established at 95�110 mg/day in the general population) from diet and do not need supplementation [122,129]. Besides, it should be considered that an excess of vitamin C ingestion leads to the opposite effect and oxidative particles are formed [130,131].

3.2. Hydroxytyrosol

dietary HydroxytyrosolHydroxytyrosol (3,4-dihydroxyphenylethanol) is a phenolic compound mainly found in olives [132].

It is considered the strongest antioxidant of olive oil and one of the main antioxidants in nature [133]. It acts as a powerful scavenger of free radicals, as a radical chain breaker and as metal chelator [134]. It has the ability of inhibiting LDL-c oxidation by macrophages [132]. In this sense, it is the only phenol recognized by the European Food Safety Authority (EFSA) as a protector of blood lipids from oxidative damage [135].

Hydroxytyrosol has also been reported to have anti-inflammatory effects, probably by suppressing cyclooxygenase activity and inducing eNOS expression [136]. Thus, enhancement of olives/olive oil intakes or hydroxytyroxol supplementation in people suffering from MetS may be a good strategy in order to improve inflammatory status.

Another beneficial effect attributed to this phenolic compound is its cardiovascular protective effect. It presents anti-atherogenic properties by decreasing the expression of vascular cell adhesion protein 1 (VCAM-1) and intercellular adhesion molecule 1 (ICAM-1) [132,137], which are probably the result of an inactivation of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF?B), activator protein 1 (AP-1), GATA transcription factor and nicotinamide adenine dinucleotide phosphate (NAD(P)H) oxidase [138,139]. Hydroxytyrosol also provides antidyslipidemic effects by lowering plasma levels of LDL-c, total cholesterol and TG, and by rising HDL-c [138].

Despite the beneficial effects attributed to hydfroxytyrosol as an antioxidant, for its antiinflamatory properties and as cardiovascular protector, it should be taken into account that most studies focused on this compound have been performed with mixtures of olive phenols, thus a synergic effect cannot be excluded [140].

3.3. Quercetin

dietaryQuercetin is a predominant flavanol naturally present in vegetables, fruits, green tea or red wine. It is commonly found as glycoside forms, where rutin is the most common and important structure found in nature [141].

Many beneficial effects that can contribute to MetS improvement have been attributed to quercetin. Among them, its antioxidant capacity should be highlighted, as it has been reported to inhibit lipid peroxidation and increase antioxidant enzymes such as superoxide dismutase (SOD), catalase (CAT) or glutathione peroxidase (GPX) [142].

Moreover, an anti-inflammatory effect mediated via attenuation of tumor necrosis factor ? (TNF-?), NF?B and mitogen-activated protein kinases (MAPK), as well as depletion of IL-6, IL-1?, IL-8 or monocyte chemoattractant protein-1 (MCP-1) gene expression has also been attributed to this polyphenol [143].

As most people with MetS are overweight or obese, the role of quercetin in body weight reduction and obesity prevention has been of special interest. In this sense, it stands out the capacity of quercetin to inhibit adipogenesis through inducing the activation of AMP-activated protein kinase (AMPK) and decreasing the expression of CCAAT-enhancer-binding protein-? (C/EBP?), peroxisome�proliferator-activated receptor gamma (PPAR?), and sterol regulatory element-binding protein 1 (SREBP-1) [141,144].

According to the antidiabetic effects, it is proposed that quercetin may act as an agonist of peroxisome proliferator-activated receptor gamma (PPAR?), and thus improve insulin-stimulated glucose uptake in mature adipocytes [145]. Moreover, quercetin may ameliorate hyperglycemia by inhibiting glucose transporter 2 (GLUT2) and insulin dependent phosphatidylinositol-3-kinase (PI3K) and blocking tyrosine kinase (TK) [142].

Finally, different studies observed that quercetin has the ability to reduce blood pressure [146�148]. However, the mechanisms of action are not clear, since some authors have suggested that quercetin increases eNOS, contributing to inhibition of platelet aggregation and improvement of the endothelial function [146,147], but there are other studies that have not come across these results [148].

3.4. Resveratrol

dietary

Resveratrol (3,5,4?-trihidroxiestilben) is a phenolic compound mainly found in red grapes and derived products (red wine, grape juice) [149]. It has shown antioxidant and anti-inflammatory activities, and cardioprotective, anti-obesity and antidiabetic capacities [150�156].

The antioxidant effects of resveratrol have been reported to be carried out by scavenging of hydroxyl, superoxide, and metal-induced radicals as well as by antioxidant effects in cells producing reactive oxygen species (ROS) [150].

Moreover, it has been reported that the anti-inflammatory effects of resveratrol are mediated by inhibiting NF?B signaling [151]. Furthermore, this polyphenol reduces the expression of proinflammatory cytokines such as interleukin 6 (IL-6), interleukin 8 (IL-8), TNF-?, monocyte chemoattractant protein-1 (MCP-1) and eNOS [152]. In addition, resveratrol inhibits the cyclooxygenase (COX) expression and activity, a pathway involved in the synthesis of proinflammatory lipid mediators [152].

Concerning the effects of resveratrol against development of type 2 diabetes, it has been reported that treatment of diabetes patients with this polyphenol provides significant improvements in the status of multiple clinically relevant biomarkers such as fasting glucose levels, insulin concentrations or glycated hemoglobin and Homeostasis Model Assessment Insulin Resistance (HOMA-IR) [153,154].

Additionally, cardioprotective effects have been attributed to resveratrol. In this sense, it is suggested that resveratrol improves the endothelial function by producing nitric oxide (NO) through increasing the activity and expression of eNOS. This effect is thought to be conducted through activation of nicotinamide adenine dinucleotide-dependent deacetylase sirtuin-1 (Sirt 1) and 5? AMP-activated protein kinase (AMPK) [155]. Besides, resveratrol exerts endothelial protection by stimulation of NF-E2-related factor 2 (Nrf2) [156] and decreasing the expression of adhesion proteins such as ICAM-1 and VCAM-1 [152].

Finally, it has been described that resveratrol may have a role in preventing obesity as it has been related with energy metabolism improvement, increasing lipolysis and reducing lipogenesis [157]. However, more studies are needed in order to corroborate these findings.

3.5. Tocopherol

dietary vitamin e TocopherolTocopherols, also known as vitamin E, are a family of eight fat-soluble phenolic compounds whose main dietary sources are vegetable oils, nuts and seeds [130,158].

For a long time, it has been suggested that vitamin E could prevent different metabolic diseases as a potent antioxidant, acting as scavenger of lipid peroxyl radicals by hydrogen donating [159]. In this sense, it was described that tocopherols inhibit peroxidation of membrane phospholipids and prevent generation of free radicals in cell membranes [160].

Moreover, it has been shown that supplementation with ?-tocopherol or ?-tocopherol, two of the different isoforms of vitamin E, could have an effect on inflammation status by reducing CRP levels [161]. Additionally, inhibition of COX and protein kinase C (PKC) and reduction of cytokines�such as IL-8 or plasminogen activator inhibitor-1 (PAI-1) are other mechanisms that may contribute to these anti-inflammatory effects [162,163].

However, the beneficial effects attributed to this vitamin previously have lately became controversial as different clinical trials have not come across such benefits, but ineffective or even harmful effects have been observed [164]. It has been recently suggested that this may be explained by the fact that vitamin E may lose most of the antioxidant capacity when ingested by human beings through different mechanisms [162].

3.6. Anthocyanins

dietary Anthocyanins

Anthocyanins are water-soluble polyphenolic compounds responsible for the red, blue and purple colors of berries, black currants, black grapes, peaches, cherries, plums, pomegranate, eggplant, black beans, red radishes, red onions, red cabbage, purple corn or purple sweet potatoes [165�167]. Actually, they are the most abundant polyphenols in fruits and vegetables [167]. Moreover, they can also be found in teas, honey, nuts, olive oil, cocoa, and cereals [168].

These compounds have high antioxidant capacity inhibiting or decreasing free radicals by donating or transferring electrons from hydrogen atoms [167].

Regarding clinical studies, it has been shown that these bioactive compounds may prevent type 2 diabetes development by improving insulin sensitivity [169]. The exact mechanisms by which anthocyanins exert their antidiabetic effect are not yet clear, but an enhancement of the glucose uptake by muscle and adipocyte cells in an insulin-independent manner has been suggested [169].

Moreover, it has been shown that anthocyanins may have the capacity to prevent CVD development by improving endothelial function via increasing brachial artery flow-mediated dilation and HDL-c, and decreasing serum VCAM-1 and LDL-c concentrations [170�173].

Finally, these polyphenolic compounds may exert anti-inflamatory effects via reducing proinflamatory molecules such as IL-8, IL-1? or CRP [172,174].

However, most studies have used anthocyanin-rich extracts instead of purified anthocyanins; thus, a synergic effect with other polyphenols cannot be discarded.

3.7. Catechins

dietary tea leaves CatechinsCatechins are polyphenols that can be found in a variety of foods including fruits, vegetables, chocolate, wine, and tea [175]. The epigallocatechin 3-gallate present in tea leaves is the catechin class most studied [176].

Anti-obesity effects have been attributed to these polyphenols in different studies [176]. The mechanisms of action suggested to explain these beneficial effects on body weight are: increasing energy expenditure and fat oxidation, and reducing fat absorption [177]. It is thought that energy expenditure is enhanced by catechol-O-methyltransferase and phosphodiesterase inhibition, which stimulates the sympathetic nervous system causing an activation of the brown adipose tissue [178]. Fat oxidation is mediated by upregulation of acyl-CoA dehydrogenase and peroxisomal b-oxidation enzymes [178,179].

Moreover, catechin intake has also been associated with lower risk of CVD development by improving lipid biomarkers. Thus, it has been reported that consumption of this kind of polyphenols may increase HDL-c and decrease LDL-c and total cholesterol [180].

Finally, and antidiabetic effect has also been related to catechin comsumption, lowering fasting glucose levels [175] and improving insulin sensitivity [178].

4. Conclusions

As the prevalence of MetS reaches epidemic rates, the finding of an effective and easy-to-follow dietary strategy to combat this heterogenic disease is still a pending subject. This work recompiled different dietary nutrients and nutritional patterns with potential benefits in the prevention and�treatment of MetS and related comorbidities (Figure 1) with the aim of facilitating future clinical�studies in this area. The challenge now is to introduce precision bioactive compounds in personalized�nutritional patterns in order to gain the most benefits for prevention and treatment of this disease�through nutrition.

dietary fig 1

Conflicts of Interest: The authors declare no conflict of interest.

blank
References:

1. Sarafidis, P.A.; Nilsson, P.M. The metabolic syndrome: A glance at its history. J. Hypertens. 2006, 24, 621�626.
[CrossRef] [PubMed]
2. Alberti, K.G.; Zimmet, P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications.
Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.
Diabet. Med. 1998, 15, 539�553. [CrossRef]
3. Balkau, B.; Charles, M.A. Comment on the provisional report from the WHO consultation. European Group
for the Study of Insulin Resistance (EGIR). Diabet. Med. 1999, 16, 442�423. [PubMed]
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive
Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on
Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA
2001, 285, 2486�2497.
5. Grundy, S.M.; Cleeman, J.I.; Daniels, S.R.; Donato, K.A.; Eckel, R.H.; Franklin, B.A.; Gordon, D.J.;
Krauss, R.M.; Savage, P.J.; Smith, S.C., Jr.; et al. Diagnosis and management of the metabolic syndrome:
An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation
2005, 112, 2735�2752. [CrossRef] [PubMed]
6. Alberti, K.G.; Zimmet, P.; Shaw, J. The metabolic syndrome�A new worldwide definition. Lancet 2005, 366,
1059�1062. [CrossRef]
7. Selassie, M.; Sinha, A.C. The epidemiology and aetiology of obesity: A global challenge. Best Pract. Res.
Clin. Anaesthesiol. 2011, 25, 1�9. [CrossRef] [PubMed]
8. WHO, W.H.O. Available online: www.who.int/mediacentre/factsheets/fs311/es/ (accessed on
4 June 2016).
9. Shimano, H. Novel qualitative aspects of tissue fatty acids related to metabolic regulation: Lessons from
Elovl6 knockout. Prog. Lipid Res. 2012, 51, 267�271. [CrossRef] [PubMed]
10. Bosomworth, N.J. Approach to identifying and managing atherogenic dyslipidemia: A metabolic
consequence of obesity and diabetes. Can. Fam. Phys. 2013, 59, 1169�1180.
11. Vidal-Puig, A. The Metabolic Syndrome and its Complex Pathophysiology. In A Systems Biology Approach to
Study Metabolic Syndrome; Oresic, M., Ed.; Springer: New York, NY, USA, 2014; pp. 3�16.
12. Poitout, V.; Robertson, R.P. Glucolipotoxicity: Fuel excess and beta-cell dysfunction. Endocr. Rev. 2008, 29,
351�366. [CrossRef] [PubMed]
13. Rizza, W.; Veronese, N.; Fontana, L. What are the roles of calorie restriction and diet quality in promoting
healthy longevity? Ageing Res. Rev. 2014, 13, 38�45. [CrossRef] [PubMed]
14. Lloyd-Jones, D.M.; Levy, D. Epidemiology of Hypertension. In Hypertension: A Companion to Braunwald�s
Heart Disease; Black, H.R., Elliott, W.J., Eds.; Elsevier: Philadephia, PA, USA, 2013; pp. 1�11.
15. Zanchetti, A. Challenges in hypertension: Prevalence, definition, mechanisms and management. J. Hypertens.
2014, 32, 451�453. [CrossRef] [PubMed]
16. Thomas, G.; Shishehbor, M.; Brill, D.; Nally, J.V., Jr. New hypertension guidelines: One size fits most?
Clevel. Clin. J. Med. 2014, 81, 178�188. [CrossRef] [PubMed]
17. James, P.A.; Oparil, S.; Carter, B.L.; Cushman, W.C.; Dennison-Himmelfarb, C.; Handler, J.; Lackland, D.T.;
LeFevre, M.L.; MacKenzie, T.D.; Ogedegbe, O.; et al. 2014 evidence-based guideline for the management
of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National
Committee (JNC 8). JAMA 2014, 311, 507�520. [CrossRef] [PubMed]
18. Klandorf, H.; Chirra, A.R.; DeGruccio, A.; Girman, D.J. Dimethyl sulfoxide modulation of diabetes onset in
NOD mice. Diabetes 1989, 38, 194�197. [CrossRef] [PubMed]
19. Ballard, K.D.; Mah, E.; Guo, Y.; Pei, R.; Volek, J.S.; Bruno, R.S. Low-fat milk ingestion prevents postprandial
hyperglycemia-mediated impairments in vascular endothelial function in obese individuals with metabolic
syndrome. J. Nutr. 2013, 143, 1602�1610. [CrossRef] [PubMed]
20. Pugliese, G.; Solini, A.; Bonora, E.; Orsi, E.; Zerbini, G.; Fondelli, C.; Gruden, G.; Cavalot, F.; Lamacchia, O.;
Trevisan, R.; et al. Distribution of cardiovascular disease and retinopathy in patients with type 2 diabetes
according to different classification systems for chronic kidney disease: A cross-sectional analysis of the
renal insufficiency and cardiovascular events (RIACE) Italian multicenter study. Cardiovasc. Diabetol. 2014,
13, 59. [PubMed]
21. Asif, M. The prevention and control the type-2 diabetes by changing lifestyle and dietary pattern. J. Educ.
Health Promot. 2014, 3, 1. [CrossRef] [PubMed]
22. Russell, W.R.; Baka, A.; Bjorck, I.; Delzenne, N.; Gao, D.; Griffiths, H.R.; Hadjilucas, E.; Juvonen, K.;
Lahtinen, S.; Lansink, M.; et al. Impact of Diet Composition on Blood Glucose Regulation. Crit. Rev. Food
Sci. Nutr. 2016, 56, 541�590. [CrossRef] [PubMed]
23. Soares, R.; Costa, C. Oxidative Stress, Inflammation and Angiogenesis in the Metabolic Syndrome; Springer:
Heidelberg, Germany, 2009.
24. Rahal, A.; Kumar, A.; Singh, V.; Yadav, B.; Tiwari, R.; Chakraborty, S.; Dhama, K. Oxidative Stress,
Prooxidants, and Antioxidants: The Interplay. BioMed Res. Int. 2014, 2014, 761264. [CrossRef] [PubMed]
25. Parthasarathy, S.; Litvinov, D.; Selvarajan, K.; Garelnabi, M. Lipid peroxidation and decomposition�Conflicting
roles in plaque vulnerability and stability. Biochim. Biophys. Acta 2008, 1781, 221�231. [CrossRef] [PubMed]
26. McGrowder, D.; Riley, C.; Morrison, E.Y.; Gordon, L. The role of high-density lipoproteins in reducing the
risk of vascular diseases, neurogenerative disorders, and cancer. Cholesterol 2011, 2011, 496925. [CrossRef]
[PubMed]
27. Ferri, N.; Ruscica, M. Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome:
Insights on insulin resistance, inflammation, and atherogenic dyslipidemia. Endocrine 2016. [CrossRef]
28. Oresic, M.; Vidal-Puig, A. A Systems Biology Approach to Study Metabolic Syndrome; Springer: Heidelberg,
Germany, 2014.
29. Lee, E.G.; Choi, J.H.; Kim, K.E.; Kim, J.H. Effects of a Walking Program on Self-management and Risk Factors
of Metabolic Syndrome in Older Korean Adults. J. Phys. Ther. Sci. 2014, 26, 105�109. [CrossRef] [PubMed]
30. Bernabe, G.J.; Zafrilla, R.P.; Mulero, C.J.; Gomez, J.P.; Leal, H.M.; Abellan, A.J. Biochemical and nutritional
markers and antioxidant activity in metabolic syndrome. Endocrinol. Nutr. 2013, 61, 302�308.
31. Bales, C.W.; Kraus, W.E. Caloric restriction: Implications for human cardiometabolic health. J. Cardiopulm.
Rehabil. Prev. 2013, 33, 201�208. [CrossRef] [PubMed]
32. Grams, J.; Garvey, W.T. Weight Loss and the Prevention and Treatment of Type 2 Diabetes Using Lifestyle
Therapy, Pharmacotherapy, and Bariatric Surgery: Mechanisms of Action. Curr. Obes. Rep. 2015, 4, 287�302.
[CrossRef] [PubMed]
33. Lazo, M.; Solga, S.F.; Horska, A.; Bonekamp, S.; Diehl, A.M.; Brancati, F.L.; Wagenknecht, L.E.; Pi-Sunyer, F.X.;
Kahn, S.E.; Clark, J.M. Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with
type 2 diabetes. Diabetes Care 2010, 33, 2156�2163. [CrossRef] [PubMed]
34. Rossmeislova, L.; Malisova, L.; Kracmerova, J.; Stich, V. Adaptation of human adipose tissue to hypocaloric
diet. Int. J. Obes. 2013, 37, 640�650. [CrossRef] [PubMed]
35. Wing, R.R.; Lang, W.; Wadden, T.A.; Safford, M.; Knowler, W.C.; Bertoni, A.G.; Hill, J.O.; Brancati, F.L.;
Peters, A.; Wagenknecht, L. Benefits of modest weight loss in improving cardiovascular risk factors in
overweight and obese individuals with type 2 diabetes. Diabetes Care 2011, 34, 1481�1486. [CrossRef]
[PubMed]
36. Golay, A.; Brock, E.; Gabriel, R.; Konrad, T.; Lalic, N.; Laville, M.; Mingrone, G.; Petrie, J.; Phan, T.M.;
Pietilainen, K.H.; et al. Taking small steps towards targets�Perspectives for clinical practice in diabetes,
cardiometabolic disorders and beyond. Int. J. Clin. Pract. 2013, 67, 322�332. [CrossRef] [PubMed]
37. Fock, K.M.; Khoo, J. Diet and exercise in management of obesity and overweight. J. Gastroenterol. Hepatol.
2013, 28, 59�63. [CrossRef] [PubMed]
38. Abete, I.; Parra, D.; Martinez, J.A. Energy-restricted diets based on a distinct food selection affecting the
glycemic index induce different weight loss and oxidative response. Clin. Nutr. 2008, 27, 545�551. [CrossRef]
[PubMed]
39. Alberti, K.G.; Eckel, R.H.; Grundy, S.M.; Zimmet, P.Z.; Cleeman, J.I.; Donato, K.A.; Fruchart, J.C.; James, W.P.;
Loria, C.M.; Smith, S.C., Jr. Harmonizing the metabolic syndrome: A joint interim statement of the
International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung,
and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis
Society; and International Association for the Study of Obesity. Circulation 2009, 120, 1640�1645. [PubMed]
40. Fleming, J.A.; Kris-Etherton, P.M. The evidence for alpha-linolenic acid and cardiovascular disease benefits:
Comparisons with eicosapentaenoic acid and docosahexaenoic acid. Adv. Nutr. 2014, 5, 863S�876S. [CrossRef]
[PubMed]
41. Gray, B.; Steyn, F.; Davies, P.S.; Vitetta, L. Omega-3 fatty acids: A review of the effects on adiponectin and
leptin and potential implications for obesity management. Eur. J. Clin. Nutr. 2013, 67, 1234�1242. [CrossRef]
[PubMed]
42. Wen, Y.T.; Dai, J.H.; Gao, Q. Effects of Omega-3 fatty acid on major cardiovascular events and mortality
in patients with coronary heart disease: A meta-analysis of randomized controlled trials. Nutr. Metab.
Cardiovasc. Dis. 2014, 24, 470�475. [CrossRef] [PubMed]
43. Lopez-Huertas, E. The effect of EPA and DHA on metabolic syndrome patients: A systematic review of
randomised controlled trials. Br. J. Nutr. 2012, 107, 185�194. [CrossRef] [PubMed]
44. Maiorino, M.I.; Chiodini, P.; Bellastella, G.; Giugliano, D.; Esposito, K. Sexual dysfunction in women with
cancer: A systematic review with meta-analysis of studies using the Female Sexual Function Index. Endocrine
2016, 54, 329�341. [CrossRef] [PubMed]
45. EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies). Scientific Opinion on Dietary
Reference Values for fats, including saturated fatty acids, polyunsaturated fatty acids, monounsaturated
fatty acids, trans fatty acids, and cholesterol1. EFSA J. 2010, 8, 1461�1566.
46. Bellastella, G.; Bizzarro, A.; Aitella, E.; Barrasso, M.; Cozzolino, D.; di Martino, S.; Esposito, K.; de Bellis, A.
Pregnancy may favour the development of severe autoimmune central diabetes insipidus in women with
vasopressin cell antibodies: Description of two cases. Eur. J. Endocrinol. 2015, 172, K11�K17. [CrossRef]
[PubMed]
47. Sun, F.H.; Li, C.; Zhang, Y.J.; Wong, S.H.; Wang, L. Effect of Glycemic Index of Breakfast on Energy Intake at
Subsequent Meal among Healthy People: A Meta-Analysis. Nutrients 2016, 8, 37. [CrossRef] [PubMed]
48. Barclay, A.W.; Brand-Miller, J.C.; Wolever, T.M. Glycemic index, glycemic load, and glycemic response are
not the same. Diabetes Care 2005, 28, 1839�1840. [CrossRef] [PubMed]
49. Nakagawa, T.; Hu, H.; Zharikov, S.; Tuttle, K.R.; Short, R.A.; Glushakova, O.; Ouyang, X.; Feig, D.I.;
Block, E.R.; Herrera-Acosta, J.; et al. A causal role for uric acid in fructose-induced metabolic syndrome.
Am. J. Physiol. Ren. Physiol. 2006, 290, F625�F631. [CrossRef] [PubMed]
50. Symons Downs, D.; Hausenblas, H.A. Women�s exercise beliefs and behaviors during their pregnancy and
postpartum. J. Midwifery Women Health 2004, 49, 138�144.
51. Brand-Miller, J.; McMillan-Price, J.; Steinbeck, K.; Caterson, I. Dietary glycemic index: Health implications.
J. Am. Coll. Nutr. 2009, 28, 446S�449S. [CrossRef] [PubMed]
52. Thomas, D.; Elliott, E.J. Low glycaemic index, or low glycaemic load, diets for diabetes mellitus.
Cochrane Database Syst. Rev. 2009. [CrossRef]
53. Barrea, L.; Balato, N.; di Somma, C.; Macchia, P.E.; Napolitano, M.; Savanelli, M.C.; Esposito, K.; Colao, A.;
Savastano, S. Nutrition and psoriasis: Is there any association between the severity of the disease and
adherence to the Mediterranean diet? J. Transl. Med. 2015, 13, 18. [CrossRef] [PubMed]
54. Mathias, K.C.; Ng, S.W.; Popkin, B. Monitoring changes in the nutritional content of ready-to-eat grain-based
dessert products manufactured and purchased between 2005 and 2012. J. Acad. Nutr. Diet. 2015, 115, 360�368.
[CrossRef] [PubMed]
55. Serafini, M.; del Rio, D. Understanding the association between dietary antioxidants, redox status and
disease: Is the Total Antioxidant Capacity the right tool? Redox Rep. 2004, 9, 145�152. [CrossRef] [PubMed]
56. Bellastella, G.; Maiorino, M.I.; Olita, L.; della Volpe, E.; Giugliano, D.; Esposito, K. Premature ejaculation is
associated with glycemic control in Type 1 diabetes. J. Sex. Med. 2015, 12, 93�99. [CrossRef] [PubMed]
57. Zulet, M.A.; Moreno-Aliaga, M.J.; Martinez, J.A. Dietary Determinants of Fat Mass and Body Composition.
In Adipose Tissue Biology; Symonds, M.E., Ed.; Springer: New York, NY, USA, 2012; pp. 271�315.
58. Carlsen, M.H.; Halvorsen, B.L.; Holte, K.; Bohn, S.K.; Dragland, S.; Sampson, L.; Willey, C.; Senoo, H.;
Umezono, Y.; Sanada, C.; et al. The total antioxidant content of more than 3100 foods, beverages, spices,
herbs and supplements used worldwide. Nutr. J. 2010, 9, 3. [CrossRef] [PubMed]
59. Harasym, J.; Oledzki, R. Effect of fruit and vegetable antioxidants on total antioxidant capacity of blood
plasma. Nutrition 2014, 30, 511�517. [CrossRef] [PubMed]
60. Maiorino, M.I.; Bellastella, G.; Petrizzo, M.; della Volpe, E.; Orlando, R.; Giugliano, D.; Esposito, K. Circulating
endothelial progenitor cells in type 1 diabetic patients with erectile dysfunction. Endocrine 2015, 49, 415�421.
[CrossRef] [PubMed]
61. Bahadoran, Z.; Golzarand, M.; Mirmiran, P.; Shiva, N.; Azizi, F. Dietary total antioxidant capacity and the
occurrence of metabolic syndrome and its components after a 3-year follow-up in adults: Tehran Lipid and
Glucose Study. Nutr. Metab. 2012, 9, 70. [CrossRef] [PubMed]
62. Chrysohoou, C.; Esposito, K.; Giugliano, D.; Panagiotakos, D.B. Peripheral Arterial Disease and
Cardiovascular Risk: The Role of Mediterranean Diet. Angiology 2015, 66, 708�710. [CrossRef] [PubMed]
63. De la Iglesia, R.; Lopez-Legarrea, P.; Celada, P.; Sanchez-Muniz, F.J.; Martinez, J.A.; Zulet, M.A. Beneficial
effects of the RESMENA dietary pattern on oxidative stress in patients suffering from metabolic syndrome
with hyperglycemia are associated to dietary TAC and fruit consumption. Int. J. Mol. Sci. 2013, 14, 6903�6919.
[CrossRef] [PubMed]
64. Lopez-Legarrea, P.; de la Iglesia, R.; Abete, I.; Bondia-Pons, I.; Navas-Carretero, S.; Forga, L.; Martinez, J.A.;
Zulet, M.A. Short-term role of the dietary total antioxidant capacity in two hypocaloric regimes on obese
with metabolic syndrome symptoms: The RESMENA randomized controlled trial. Nutr. Metab. 2013, 10, 22.
[CrossRef] [PubMed]
65. Puchau, B.; Zulet, M.A.; de Echavarri, A.G.; Hermsdorff, H.H.; Martinez, J.A. Dietary total antioxidant
capacity is negatively associated with some metabolic syndrome features in healthy young adults. Nutrition
2010, 26, 534�541. [CrossRef] [PubMed]
66. World Health Organization. Obesity: Preventing and Managing the Global Epidemic; Report of a WHO
Consultation; World Health Organization Technical Report Series; WHO: Geneva, Switzerland, 2000.
67. Tapsell, L.C.; Hemphill, I.; Cobiac, L.; Patch, C.S.; Sullivan, D.R.; Fenech, M.; Roodenrys, S.; Keogh, J.B.;
Clifton, P.M.; Williams, P.G.; et al. Health benefits of herbs and spices: The past, the present, the future.
Med. J. Aust. 2006, 185, S4�S24. [PubMed]
68. Abete, I.; Astrup, A.; Martinez, J.A.; Thorsdottir, I.; Zulet, M.A. Obesity and the metabolic syndrome: Role of
different dietary macronutrient distribution patterns and specific nutritional components on weight loss and
maintenance. Nutr. Rev. 2010, 68, 214�231. [CrossRef] [PubMed]
69. Ebbeling, C.B.; Swain, J.F.; Feldman, H.A.; Wong, W.W.; Hachey, D.L.; Garcia-Lago, E.; Ludwig, D.S. Effects
of dietary composition on energy expenditure during weight-loss maintenance. JAMA 2012, 307, 2627�2634.
[CrossRef] [PubMed]
70. Abete, I.; Goyenechea, E.; Zulet, M.A.; Martinez, J.A. Obesity and metabolic syndrome: Potential benefit
from specific nutritional components. Nutr. Metab. Cardiovasc. Dis. 2011, 21, B1�B15. [CrossRef] [PubMed]
71. Arciero, P.J.; Ormsbee, M.J.; Gentile, C.L.; Nindl, B.C.; Brestoff, J.R.; Ruby, M. Increased protein intake and
meal frequency reduces abdominal fat during energy balance and energy deficit. Obesity 2013, 21, 1357�1366.
[CrossRef] [PubMed]
72. Wikarek, T.; Chudek, J.; Owczarek, A.; Olszanecka-Glinianowicz, M. Effect of dietary macronutrients on
postprandial incretin hormone release and satiety in obese and normal-weight women. Br. J. Nutr. 2014, 111,
236�246. [CrossRef] [PubMed]
73. Bray, G.A.; Smith, S.R.; de Jonge, L.; Xie, H.; Rood, J.; Martin, C.K.; Most, M.; Brock, C.; Mancuso, S.;
Redman, L.M. Effect of dietary protein content on weight gain, energy expenditure, and body composition
during overeating: A randomized controlled trial. JAMA 2012, 307, 47�55. [CrossRef] [PubMed]
74. Westerterp-Plantenga, M.S.; Nieuwenhuizen, A.; Tome, D.; Soenen, S.; Westerterp, K.R. Dietary protein,
weight loss, and weight maintenance. Annu. Rev. Nutr. 2009, 29, 21�41. [CrossRef] [PubMed]
75. Koppes, L.L.; Boon, N.; Nooyens, A.C.; van Mechelen, W.; Saris, W.H. Macronutrient distribution over
a period of 23 years in relation to energy intake and body fatness. Br. J. Nutr. 2009, 101, 108�115. [CrossRef]
[PubMed]
76. De Jonge, L.; Bray, G.A.; Smith, S.R.; Ryan, D.H.; de Souza, R.J.; Loria, C.M.; Champagne, C.M.;
Williamson, D.A.; Sacks, F.M. Effect of diet composition and weight loss on resting energy expenditure in
the POUNDS LOST study. Obesity 2012, 20, 2384�2389. [CrossRef] [PubMed]
77. Stocks, T.; Angquist, L.; Hager, J.; Charon, C.; Holst, C.; Martinez, J.A.; Saris, W.H.; Astrup, A.; Sorensen, T.I.;
Larsen, L.H. TFAP2B-dietary protein and glycemic index interactions and weight maintenance after weight
loss in the DiOGenes trial. Hum. Hered. 2013, 75, 213�219. [CrossRef] [PubMed]
78. Giugliano, D.; Maiorino, M.I.; Esposito, K. Linking prediabetes and cancer: A complex issue. Diabetologia
2015, 58, 201�202. [CrossRef] [PubMed]
79. Bendtsen, L.Q.; Lorenzen, J.K.; Bendsen, N.T.; Rasmussen, C.; Astrup, A. Effect of dairy proteins on appetite,
energy expenditure, body weight, and composition: A review of the evidence from controlled clinical trials.
Adv. Nutr. 2013, 4, 418�438. [CrossRef] [PubMed]
80. Heer, M.; Egert, S. Nutrients other than carbohydrates: Their effects on glucose homeostasis in humans.
Diabetes Metab. Res. Rev. 2015, 31, 14�35. [CrossRef] [PubMed]
81. Layman, D.K.; Evans, E.M.; Erickson, D.; Seyler, J.; Weber, J.; Bagshaw, D.; Griel, A.; Psota, T.; Kris-Etherton, P.
A moderate-protein diet produces sustained weight loss and long-term changes in body composition and
blood lipids in obese adults. J. Nutr. 2009, 139, 514�521. [CrossRef] [PubMed]
82. Pedersen, A.N.; Kondrup, J.; Borsheim, E. Health effects of protein intake in healthy adults: A systematic
literature review. Food Nutr. Res. 2013, 57, 21245. [CrossRef] [PubMed]
83. Daly, R.M.; O�Connell, S.L.; Mundell, N.L.; Grimes, C.A.; Dunstan, D.W.; Nowson, C.A. Protein-enriched
diet, with the use of lean red meat, combined with progressive resistance training enhances lean tissue mass
and muscle strength and reduces circulating IL-6 concentrations in elderly women: A cluster randomized
controlled trial. Am. J. Clin. Nutr. 2014, 99, 899�910. [CrossRef] [PubMed]
84. Arciero, P.J.; Gentile, C.L.; Pressman, R.; Everett, M.; Ormsbee, M.J.; Martin, J.; Santamore, J.; Gorman, L.;
Fehling, P.C.; Vukovich, M.D.; et al. Moderate protein intake improves total and regional body composition
and insulin sensitivity in overweight adults. Metab. Clin. Exp. 2008, 57, 757�765. [CrossRef] [PubMed]
85. Gregory, S.M.; Headley, S.A.; Wood, R.J. Effects of dietary macronutrient distribution on vascular integrity in
obesity and metabolic syndrome. Nutr. Rev. 2011, 69, 509�519. [CrossRef] [PubMed]
86. Consenso FESNAD-SEEDO. Recomendaciones nutricionales basadas en la evidencia para la prevenci�n y el
tratamiento del sobrepeso y la obesidad en adultos (Consenso FESNAD-SEEDO). Rev. Esp. Obes. 2011, 10, 36.
87. Jakubowicz, D.; Froy, O.; Wainstein, J.; Boaz, M. Meal timing and composition influence ghrelin levels,
appetite scores and weight loss maintenance in overweight and obese adults. Steroids 2012, 77, 323�331.
[CrossRef] [PubMed]
88. Schwarz, N.A.; Rigby, B.R.; La Bounty, P.; Shelmadine, B.; Bowden, R.G. A review of weight control strategies
and their effects on the regulation of hormonal balance. J. Nutr. Metab. 2011, 2011, 237932. [CrossRef]
[PubMed]
89. Ohkawara, K.; Cornier, M.A.; Kohrt, W.M.; Melanson, E.L. Effects of increased meal frequency on fat
oxidation and perceived hunger. Obesity 2013, 21, 336�343. [CrossRef] [PubMed]
90. Ekmekcioglu, C.; Touitou, Y. Chronobiological aspects of food intake and metabolism and their relevance on
energy balance and weight regulation. Obes. Rev. 2011, 12, 14�25. [CrossRef] [PubMed]
91. Lioret, S.; Touvier, M.; Lafay, L.; Volatier, J.L.; Maire, B. Are eating occasions and their energy content related
to child overweight and socioeconomic status? Obesity 2008, 16, 2518�2523. [CrossRef] [PubMed]
92. Bhutani, S.; Varady, K.A. Nibbling versus feasting: Which meal pattern is better for heart disease prevention?
Nutr. Rev. 2009, 67, 591�598. [CrossRef] [PubMed]
93. Leidy, H.J.; Tang, M.; Armstrong, C.L.; Martin, C.B.; Campbell, W.W. The effects of consuming frequent,
higher protein meals on appetite and satiety during weight loss in overweight/obese men. Obesity 2011, 19,
818�824. [CrossRef] [PubMed]
94. Mills, J.P.; Perry, C.D.; Reicks, M. Eating frequency is associated with energy intake but not obesity in midlife
women. Obesity 2011, 19, 552�559. [CrossRef] [PubMed]
95. Cameron, J.D.; Cyr, M.J.; Doucet, E. Increased meal frequency does not promote greater weight loss in subjects
who were prescribed an 8-week equi-energetic energy-restricted diet. Br. J. Nutr. 2010, 103, 1098�1101.
[CrossRef] [PubMed]
96. Smeets, A.J.; Lejeune, M.P.; Westerterp-Plantenga, M.S. Effects of oral fat perception by modified sham
feeding on energy expenditure, hormones and appetite profile in the postprandial state. Br. J. Nutr. 2009,
101, 1360�1368. [CrossRef] [PubMed]
97. Taylor, M.A.; Garrow, J.S. Compared with nibbling, neither gorging nor a morning fast affect short-term
energy balance in obese patients in a chamber calorimeter. Int. J. Obes. Relat. Metab. Disord. 2001, 25, 519�528.
[CrossRef] [PubMed]
98. Smeets, A.J.; Westerterp-Plantenga, M.S. Acute effects on metabolism and appetite profile of one meal
difference in the lower range of meal frequency. Br. J. Nutr. 2008, 99, 1316�1321. [CrossRef] [PubMed]
99. Heden, T.D.; LeCheminant, J.D.; Smith, J.D. Influence of weight classification on walking and jogging energy
expenditure prediction in women. Res. Q. Exerc. Sport 2012, 83, 391�399. [CrossRef] [PubMed]
100. Bachman, J.L.; Raynor, H.A. Effects of manipulating eating frequency during a behavioral weight loss
intervention: A pilot randomized controlled trial. Obesity 2012, 20, 985�992. [CrossRef] [PubMed]
101. Perrigue, M.M.; Drewnowski, A.; Wang, C.Y.; Neuhouser, M.L. Higher Eating Frequency Does Not Decrease
Appetite in Healthy Adults. J. Nutr. 2016, 146, 59�64. [CrossRef] [PubMed]
102. Keys, A. Coronary heart disease in seven countries. 1970. Nutrition 1997, 13, 249�253. [CrossRef]
103. Keys, A.; Menotti, A.; Aravanis, C.; Blackburn, H.; Djordevic, B.S.; Buzina, R.; Dontas, A.S.; Fidanza, F.;
Karvonen, M.J.; Kimura, N.; et al. The seven countries study: 2289 deaths in 15 years. Prev. Med. 1984, 13,
141�154. [CrossRef]
104. Davis, C.; Bryan, J.; Hodgson, J.; Murphy, K. Definition of the Mediterranean Diet; a Literature Review.
Nutrients 2015, 7, 9139�9153. [CrossRef] [PubMed]
105. Sofi, F.; Macchi, C.; Abbate, R.; Gensini, G.F.; Casini, A. Mediterranean diet and health status: An updated
meta-analysis and a proposal for a literature-based adherence score. Public Health Nutr. 2014, 17, 2769�2782.
[CrossRef] [PubMed]
106. Mayneris-Perxachs, J.; Sala-Vila, A.; Chisaguano, M.; Castellote, A.I.; Estruch, R.; Covas, M.I.; Fito, M.;
Salas-Salvado, J.; Martinez-Gonzalez, M.A.; Lamuela-Raventos, R.; et al. Effects of 1-year intervention with
a Mediterranean diet on plasma fatty acid composition and metabolic syndrome in a population at high
cardiovascular risk. PLoS ONE 2014, 9, e85202. [CrossRef] [PubMed]
107. Esposito, K.; Maiorino, M.I.; Bellastella, G.; Chiodini, P.; Panagiotakos, D.; Giugliano, D. A journey
into a Mediterranean diet and type 2 diabetes: A systematic review with meta-analyses. BMJ Open
2015, 5, e008222. [CrossRef] [PubMed]
108. Kastorini, C.M.; Milionis, H.J.; Esposito, K.; Giugliano, D.; Goudevenos, J.A.; Panagiotakos, D.B. The effect of
Mediterranean diet on metabolic syndrome and its components: A meta-analysis of 50 studies and 534,906
individuals. J. Am. Coll. Cardiol. 2011, 57, 1299�1313. [CrossRef] [PubMed]
109. Schwingshackl, L.; Missbach, B.; Konig, J.; Hoffmann, G. Adherence to a Mediterranean diet and risk of
diabetes: A systematic review and meta-analysis. Public Health Nutr. 2015, 18, 1292�1299. [CrossRef]
[PubMed]
110. Koloverou, E.; Esposito, K.; Giugliano, D.; Panagiotakos, D. The effect of Mediterranean diet on the
development of type 2 diabetes mellitus: A meta-analysis of 10 prospective studies and 136,846 participants.
Metab. Clin. Exp. 2014, 63, 903�911. [CrossRef] [PubMed]
111. Salas-Salvado, J.; Garcia-Arellano, A.; Estruch, R.; Marquez-Sandoval, F.; Corella, D.; Fiol, M.;
Gomez-Gracia, E.; Vinoles, E.; Aros, F.; Herrera, C.; et al. Components of the Mediterranean-type food
pattern and serum inflammatory markers among patients at high risk for cardiovascular disease. Eur. J.
Clin. Nutr. 2008, 62, 651�659. [CrossRef] [PubMed]
112. Martinez-Gonzalez, M.A.; Garcia-Lopez, M.; Bes-Rastrollo, M.; Toledo, E.; Martinez-Lapiscina, E.H.;
Delgado-Rodriguez, M.; Vazquez, Z.; Benito, S.; Beunza, J.J. Mediterranean diet and the incidence of
cardiovascular disease: A Spanish cohort. Nutr. Metab. Cardiovasc. Dis. 2011, 21, 237�244. [CrossRef]
[PubMed]
113. Fito, M.; Estruch, R.; Salas-Salvado, J.; Martinez-Gonzalez, M.A.; Aros, F.; Vila, J.; Corella, D.; Diaz, O.;
Saez, G.; de la Torre, R.; et al. Effect of the Mediterranean diet on heart failure biomarkers: A randomized
sample from the PREDIMED trial. Eur. J. Heart Fail. 2014, 16, 543�550. [CrossRef] [PubMed]
114. Estruch, R.; Ros, E.; Salas-Salvado, J.; Covas, M.I.; Corella, D.; Aros, F.; Gomez-Gracia, E.; Ruiz-Gutierrez, V.;
Fiol, M.; Lapetra, J.; et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N. Engl.
J. Med. 2013, 368, 1279�1290. [CrossRef] [PubMed]
115. Serra-Majem, L.; Roman, B.; Estruch, R. Scientific evidence of interventions using the Mediterranean diet:
A systematic review. Nutr. Rev. 2006, 64, S27�S47. [CrossRef] [PubMed]
116. Esposito, K.; Kastorini, C.M.; Panagiotakos, D.B.; Giugliano, D. Mediterranean diet and weight loss:
Meta-analysis of randomized controlled trials. Metab. Syndr. Relat. Disord. 2011, 9, 1�12. [CrossRef]
[PubMed]
117. Razquin, C.; Martinez, J.A.; Martinez-Gonzalez, M.A.; Mitjavila, M.T.; Estruch, R.; Marti, A. A 3 years
follow-up of a Mediterranean diet rich in virgin olive oil is associated with high plasma antioxidant capacity
and reduced body weight gain. Eur. J. Clin. Nutr. 2009, 63, 1387�1393. [CrossRef] [PubMed]
118. Bertoli, S.; Spadafranca, A.; Bes-Rastrollo, M.; Martinez-Gonzalez, M.A.; Ponissi, V.; Beggio, V.; Leone, A.;
Battezzati, A. Adherence to the Mediterranean diet is inversely related to binge eating disorder in patients
seeking a weight loss program. Clin. Nutr. 2015, 34, 107�114. [CrossRef] [PubMed]
119. Rios-Hoyo, A.; Cortes, M.J.; Rios-Ontiveros, H.; Meaney, E.; Ceballos, G.; Gutierrez-Salmean, G. Obesity,
Metabolic Syndrome, and Dietary Therapeutical Approaches with a Special Focus on Nutraceuticals
(Polyphenols): A Mini-Review. Int. J. Vitam. Nutr. Res. 2014, 84, 113�123. [CrossRef] [PubMed]
120. Juraschek, S.P.; Guallar, E.; Appel, L.J.; Miller, E.R., 3rd. Effects of vitamin C supplementation on blood
pressure: A meta-analysis of randomized controlled trials. Am. J. Clin. Nutr. 2012, 95, 1079�1088. [CrossRef]
[PubMed]
121. Michels, A.J.; Frei, B. Myths, artifacts, and fatal flaws: Identifying limitations and opportunities in vitamin C
research. Nutrients 2013, 5, 5161�5192. [CrossRef] [PubMed]
122. Frei, B.; Birlouez-Aragon, I.; Lykkesfeldt, J. Authors� perspective: What is the optimum intake of vitamin C
in humans? Crit. Rev. Food Sci. Nutr. 2012, 52, 815�829. [CrossRef] [PubMed]
123. Mason, S.A.; della Gatta, P.A.; Snow, R.J.; Russell, A.P.; Wadley, G.D. Ascorbic acid supplementation
improves skeletal muscle oxidative stress and insulin sensitivity in people with type 2 diabetes: Findings of
a randomized controlled study. Free Radic. Biol. Med. 2016, 93, 227�238. [CrossRef] [PubMed]
124. Chambial, S.; Dwivedi, S.; Shukla, K.K.; John, P.J.; Sharma, P. Vitamin C in Disease Prevention and Cure:
An Overview. Indian J. Clin. Biochem. 2013, 28, 314�328. [CrossRef] [PubMed]
125. Block, G.; Jensen, C.D.; Dalvi, T.B.; Norkus, E.P.; Hudes, M.; Crawford, P.B.; Holland, N.; Fung, E.B.;
Schumacher, L.; Harmatz, P. Vitamin C treatment reduces elevated C-reactive protein. Free Radic. Biol. Med.
2009, 46, 70�77. [CrossRef] [PubMed]
126. Ashor, A.W.; Siervo, M.; Lara, J.; Oggioni, C.; Afshar, S.; Mathers, J.C. Effect of vitamin C and vitamin E
supplementation on endothelial function: A systematic review and meta-analysis of randomised controlled
trials. Br. J. Nutr. 2015, 113, 1182�1194. [CrossRef] [PubMed]
127. Kim, S.M.; Lim, S.M.; Yoo, J.A.; Woo, M.J.; Cho, K.H. Consumption of high-dose vitamin C (1250 mg
per day) enhances functional and structural properties of serum lipoprotein to improve anti-oxidant,
anti-atherosclerotic, and anti-aging effects via regulation of anti-inflammatory microRNA. Food Funct.
2015, 6, 3604�3612. [CrossRef] [PubMed]
128. Monfared, S.; Larijani, B.; Abdollahi, M. Islet transplantation and antioxidant management: A comprehensive
review. World J. Gastroenterol. 2009, 15, 1153�1161. [CrossRef]
129. German Nutrition Society (DGE). New Reference Values for Vitamin C Intake. Ann. Nutr. Metab. 2015,
67, 13�20.
130. Mamede, A.C.; Tavares, S.D.; Abrantes, A.M.; Trindade, J.; Maia, J.M.; Botelho, M.F. The role of vitamins in
cancer: A review. Nutr. Cancer 2011, 63, 479�494. [CrossRef] [PubMed]
131. Moser, M.A.; Chun, O.K. Vitamin C and Heart Health: A Review Based on Findings from Epidemiologic
Studies. Int. J. Mol. Sci. 2016, 17, 1328. [CrossRef] [PubMed]
132. Vilaplana-Perez, C.; Aunon, D.; Garcia-Flores, L.A.; Gil-Izquierdo, A. Hydroxytyrosol and potential uses in
cardiovascular diseases, cancer, and AIDS. Front. Nutr. 2014, 1, 18. [PubMed]
133. Achmon, Y.; Fishman, A. The antioxidant hydroxytyrosol: Biotechnological production challenges and
opportunities. Appl. Microbiol. Biotechnol. 2015, 99, 1119�1130. [CrossRef] [PubMed]
134. Bulotta, S.; Celano, M.; Lepore, S.M.; Montalcini, T.; Pujia, A.; Russo, D. Beneficial effects of the olive
oil phenolic components oleuropein and hydroxytyrosol: Focus on protection against cardiovascular and
metabolic diseases. J. Transl. Med. 2014, 12, 219. [CrossRef] [PubMed]
135. EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies). Scientific Opinion on the
substantiation of health claims related to polyphenols in olive and protection of LDL particles from oxidative
damage (ID 1333, 1638, 1639, 1696, 2865), maintenance of normal blood HDL cholesterol concentrations
(ID 1639). EFSA J. 2011, 9, 2033�2058.
136. Scoditti, E.; Nestola, A.; Massaro, M.; Calabriso, N.; Storelli, C.; De Caterina, R.; Carluccio, M.A.
Hydroxytyrosol suppresses MMP-9 and COX-2 activity and expression in activated human monocytes
via PKCalpha and PKCbeta1 inhibition. Atherosclerosis 2014, 232, 17�24. [CrossRef] [PubMed]
137. Giordano, E.; Dangles, O.; Rakotomanomana, N.; Baracchini, S.; Visioli, F. 3-O-Hydroxytyrosol glucuronide
and 4-O-hydroxytyrosol glucuronide reduce endoplasmic reticulum stress in vitro. Food Funct. 2015, 6,
3275�3281. [CrossRef] [PubMed]
138. Granados-Principal, S.; Quiles, J.L.; Ramirez-Tortosa, C.L.; Sanchez-Rovira, P.; Ramirez-Tortosa, M.C.
Hydroxytyrosol: From laboratory investigations to future clinical trials. Nutr. Rev. 2010, 68, 191�206.
[CrossRef] [PubMed]
139. Carluccio, M.A.; Siculella, L.; Ancora, M.A.; Massaro, M.; Scoditti, E.; Storelli, C.; Visioli, F.;
Distante, A.; De Caterina, R. Olive oil and red wine antioxidant polyphenols inhibit endothelial activation:
Antiatherogenic properties of Mediterranean diet phytochemicals. Arterioscler. Thromb. Vasc. Biol. 2003, 23,
622�629. [CrossRef] [PubMed]
140. Visioli, F.; Bernardini, E. Extra virgin olive oil�s polyphenols: Biological activities. Curr. Pharm. Des. 2011, 17,
786�804. [CrossRef] [PubMed]
141. Nabavi, S.F.; Russo, G.L.; Daglia, M.; Nabavi, S.M. Role of quercetin as an alternative for obesity treatment:
You are what you eat! Food Chem. 2015, 179, 305�310. [CrossRef] [PubMed]
142. Vinayagam, R.; Xu, B. Antidiabetic properties of dietary flavonoids: A cellular mechanism review.
Nutr. Metab. 2015, 12, 60. [CrossRef] [PubMed]
143. Shibata, T.; Nakashima, F.; Honda, K.; Lu, Y.J.; Kondo, T.; Ushida, Y.; Aizawa, K.; Suganuma, H.; Oe, S.;
Tanaka, H.; et al. Toll-like receptors as a target of food-derived anti-inflammatory compounds. J. Biol. Chem.
2014, 289, 32757�32772. [CrossRef] [PubMed]
144. Ahn, J.; Lee, H.; Kim, S.; Park, J.; Ha, T. The anti-obesity effect of quercetin is mediated by the AMPK and
MAPK signaling pathways. Biochem. Biophys. Res. Commun. 2008, 373, 545�549. [CrossRef] [PubMed]
145. Fang, X.K.; Gao, J.; Zhu, D.N. Kaempferol and quercetin isolated from Euonymus alatus improve glucose
uptake of 3T3-L1 cells without adipogenesis activity. Life Sci. 2008, 82, 615�622. [CrossRef] [PubMed]
146. Clark, J.L.; Zahradka, P.; Taylor, C.G. Efficacy of flavonoids in the management of high blood pressure.
Nutr. Rev. 2015, 73, 799�822. [CrossRef] [PubMed]
147. D�Andrea, G. Quercetin: A flavonol with multifaceted therapeutic applications? Fitoterapia 2015, 106, 256�271.
[CrossRef] [PubMed]
148. Larson, A.; Witman, M.A.; Guo, Y.; Ives, S.; Richardson, R.S.; Bruno, R.S.; Jalili, T.; Symons, J.D. Acute,
quercetin-induced reductions in blood pressure in hypertensive individuals are not secondary to lower
plasma angiotensin-converting enzyme activity or endothelin-1: Nitric oxide. Nutr. Res. 2012, 32, 557�564.
[CrossRef] [PubMed]
149. Tome-Carneiro, J.; Gonzalvez, M.; Larrosa, M.; Yanez-Gascon, M.J.; Garcia-Almagro, F.J.; Ruiz-Ros, J.A.;
Tomas-Barberan, F.A.; Garcia-Conesa, M.T.; Espin, J.C. Resveratrol in primary and secondary prevention of
cardiovascular disease: A dietary and clinical perspective. Ann. N. Y. Acad. Sci. 2013, 1290, 37�51. [CrossRef]
[PubMed]
150. Leonard, S.S.; Xia, C.; Jiang, B.H.; Stinefelt, B.; Klandorf, H.; Harris, G.K.; Shi, X. Resveratrol scavenges
reactive oxygen species and effects radical-induced cellular responses. Biochem. Biophys. Res. Commun. 2003,
309, 1017�1026. [CrossRef] [PubMed]
151. Ren, Z.; Wang, L.; Cui, J.; Huoc, Z.; Xue, J.; Cui, H.; Mao, Q.; Yang, R. Resveratrol inhibits NF-?B signaling
through suppression of p65 and I?B kinase activities. Die Pharm. 2013, 68, 689�694.
152. Latruffe, N.; Lancon, A.; Frazzi, R.; Aires, V.; Delmas, D.; Michaille, J.J.; Djouadi, F.; Bastin, J.;
Cherkaoui-Malki, M. Exploring new ways of regulation by resveratrol involving miRNAs, with emphasis on
inflammation. Ann. N. Y. Acad. Sci. 2015, 1348, 97�106. [CrossRef] [PubMed]
153. Hausenblas, H.A.; Schoulda, J.A.; Smoliga, J.M. Resveratrol treatment as an adjunct to pharmacological
management in type 2 diabetes mellitus�Systematic review and meta-analysis. Mol. Nutr. Food Res. 2015,
59, 147�159. [CrossRef] [PubMed]
154. Liu, K.; Zhou, R.; Wang, B.; Mi, M.T. Effect of resveratrol on glucose control and insulin sensitivity:
A meta-analysis of 11 randomized controlled trials. Am. J. Clin. Nutr. 2014, 99, 1510�1519. [CrossRef]
[PubMed]
155. Bitterman, J.L.; Chung, J.H. Metabolic effects of resveratrol: Addressing the controversies. Cell. Mol. Life Sci.
2015, 72, 1473�1488. [CrossRef] [PubMed]
156. Han, S.; Park, J.S.; Lee, S.; Jeong, A.L.; Oh, K.S.; Ka, H.I.; Choi, H.J.; Son, W.C.; Lee, W.Y.; Oh, S.J.; et al.
CTRP1 protects against diet-induced hyperglycemia by enhancing glycolysis and fatty acid oxidation.
J. Nutr. Biochem. 2016, 27, 43�52. [CrossRef] [PubMed]
157. Gambini, J.; Ingles, M.; Olaso, G.; Lopez-Grueso, R.; Bonet-Costa, V.; Gimeno-Mallench, L.; Mas-Bargues, C.;
Abdelaziz, K.M.; Gomez-Cabrera, M.C.; Vina, J.; et al. Properties of Resveratrol: In Vitro and In Vivo
Studies about Metabolism, Bioavailability, and Biological Effects in Animal Models and Humans. Oxid. Med.
Cell. Longev. 2015, 2015, 837042. [CrossRef] [PubMed]
158. Yang, C.S.; Suh, N. Cancer prevention by different forms of tocopherols. Top. Curr. Chem. 2013, 329, 21�33.
[PubMed]
159. Jiang, Q. Natural forms of vitamin E: Metabolism, antioxidant, and anti-inflammatory activities and their
role in disease prevention and therapy. Free Radic. Biol. Med. 2014, 72, 76�90. [CrossRef] [PubMed]
160. Witting, P.K.; Upston, J.M.; Stocker, R. The molecular action of alpha-tocopherol in lipoprotein lipid
peroxidation. Pro- and antioxidant activity of vitamin E in complex heterogeneous lipid emulsions.
In Fat-Soluble Vitamins; Quinn, P.J., Kagan, V.E., Eds.; Springer: New York, NY, USA; pp. 345�390.
161. Saboori, S.; Shab-Bidar, S.; Speakman, J.R.; Yousefi Rad, E.; Djafarian, K. Effect of vitamin E supplementation
on serum C-reactive protein level: A meta-analysis of randomized controlled trials. Eur. J. Clin. Nutr. 2015,
69, 867�873. [CrossRef] [PubMed]
162. Azzi, A.; Meydani, S.N.; Meydani, M.; Zingg, J.M. The rise, the fall and the renaissance of vitamin E.
Arch. Biochem. Biophys. 2016, 595, 100�108. [CrossRef] [PubMed]
163. Raederstorff, D.; Wyss, A.; Calder, P.C.; Weber, P.; Eggersdorfer, M. Vitamin E function and requirements in
relation to PUFA. Br. J. Nutr. 2015, 114, 1113�1122. [CrossRef] [PubMed]
164. Loffredo, L.; Perri, L.; Di Castelnuovo, A.; Iacoviello, L.; De Gaetano, G.; Violi, F. Supplementation
with vitamin E alone is associated with reduced myocardial infarction: A meta-analysis. Nutr. Metab.
Cardiovasc. Dis. 2015, 25, 354�363. [CrossRef] [PubMed]
165. Giampieri, F.; Tulipani, S.; Alvarez-Suarez, J.M.; Quiles, J.L.; Mezzetti, B.; Battino, M. The strawberry:
Composition, nutritional quality, and impact on human health. Nutrition 2012, 28, 9�19. [CrossRef] [PubMed]
166. Amiot, M.J.; Riva, C.; Vinet, A. Effects of dietary polyphenols on metabolic syndrome features in humans:
A systematic review. Obes. Rev. 2016, 17, 573�586. [CrossRef] [PubMed]
167. Smeriglio, A.; Barreca, D.; Bellocco, E.; Trombetta, D. Chemistry, Pharmacology and Health Benefits of
Anthocyanins. Phytother. Res. 2016, 30, 1265�1286. [CrossRef] [PubMed]
168. Lila, M.A. Anthocyanins and Human Health: An In Vitro Investigative Approach. J. Biomed. Biotechnol. 2004,
2004, 306�313. [CrossRef] [PubMed]
169. Stull, A.J.; Cash, K.C.; Johnson, W.D.; Champagne, C.M.; Cefalu, W.T. Bioactives in blueberries improve
insulin sensitivity in obese, insulin-resistant men and women. J. Nutr. 2010, 140, 1764�1768. [CrossRef]
[PubMed]
170. Zhu, Y.; Xia, M.; Yang, Y.; Liu, F.; Li, Z.; Hao, Y.; Mi, M.; Jin, T.; Ling, W. Purified anthocyanin supplementation
improves endothelial function via NO-cGMP activation in hypercholesterolemic individuals. Clin. Chem.
2011, 57, 1524�1533. [CrossRef] [PubMed]
171. Qin, Y.; Xia, M.; Ma, J.; Hao, Y.; Liu, J.; Mou, H.; Cao, L.; Ling, W. Anthocyanin supplementation improves
serum LDL- and HDL-cholesterol concentrations associated with the inhibition of cholesteryl ester transfer
protein in dyslipidemic subjects. Am. J. Clin. Nutr. 2009, 90, 485�492. [CrossRef] [PubMed]
172. Zhu, Y.; Ling, W.; Guo, H.; Song, F.; Ye, Q.; Zou, T.; Li, D.; Zhang, Y.; Li, G.; Xiao, Y.; et al. Anti-inflammatory
effect of purified dietary anthocyanin in adults with hypercholesterolemia: A randomized controlled trial.
Nutr. Metab. Cardiovasc. Dis. 2013, 23, 843�849. [CrossRef] [PubMed]
173. Zhu, Y.; Huang, X.; Zhang, Y.; Wang, Y.; Liu, Y.; Sun, R.; Xia, M. Anthocyanin supplementation
improves HDL-associated paraoxonase 1 activity and enhances cholesterol efflux capacity in subjects
with hypercholesterolemia. J. Clin. Endocrinol. Metab. 2014, 99, 561�569. [CrossRef] [PubMed]
174. Karlsen, A.; Retterstol, L.; Laake, P.; Paur, I.; Bohn, S.K.; Sandvik, L.; Blomhoff, R. Anthocyanins inhibit
nuclear factor-kappaB activation in monocytes and reduce plasma concentrations of pro-inflammatory
mediators in healthy adults. J. Nutr. 2007, 137, 1951�1954. [PubMed]
175. Keske, M.A.; Ng, H.L.; Premilovac, D.; Rattigan, S.; Kim, J.A.; Munir, K.; Yang, P.; Quon, M.J. Vascular and
metabolic actions of the green tea polyphenol epigallocatechin gallate. Curr. Med. Chem. 2015, 22, 59�69.
[CrossRef] [PubMed]
176. Johnson, R.; Bryant, S.; Huntley, A.L. Green tea and green tea catechin extracts: An overview of the clinical
evidence. Maturitas 2012, 73, 280�287. [CrossRef] [PubMed]
177. Huang, J.; Wang, Y.; Xie, Z.; Zhou, Y.; Zhang, Y.; Wan, X. The anti-obesity effects of green tea in human
intervention and basic molecular studies. Eur. J. Clin. Nutr. 2014, 68, 1075�1087. [CrossRef] [PubMed]
178. Hursel, R.; Westerterp-Plantenga, M.S. Catechin- and caffeine-rich teas for control of body weight in humans.
Am. J. Clin. Nutr. 2013, 98, 1682S�1693S. [CrossRef] [PubMed]
179. Gutierrez-Salmean, G.; Ortiz-Vilchis, P.; Vacaseydel, C.M.; Rubio-Gayosso, I.; Meaney, E.; Villarreal, F.;
Ramirez-Sanchez, I.; Ceballos, G. Acute effects of an oral supplement of (?)-epicatechin on postprandial fat
and carbohydrate metabolism in normal and overweight subjects. Food Funct. 2014, 5, 521�527. [CrossRef]
[PubMed]
180. Khalesi, S.; Sun, J.; Buys, N.; Jamshidi, A.; Nikbakht-Nasrabadi, E.; Khosravi-Boroujeni, H. Green tea
catechins and blood pressure: A systematic review and meta-analysis of randomised controlled trials.
Eur. J. Nutr. 2014, 53, 1299�1311. [CrossRef] [PubMed]

Close Accordion
Lifestyle Changes for Managing Thyroid Disease | Wellness Clinic

Lifestyle Changes for Managing Thyroid Disease | Wellness Clinic

A butterfly-shaped gland found at the front of the neck, the thyroid gland, may not look like much, but it can wreak havoc on your health, when it isn’t functioning properly. The thyroid gland produces thyroxin (T4) and triiodothyronine (T3), hormones which control the metabolism, respiration, temperature and other essential functions of the human body. Too much or too little of these hormones can lead to thyroid disease, such as hypothyroidism and hyperthyroidism.

 

What can you do to treat thyroid disorders?

 

To treat thyroid disorders, drugs and medications are often prescribed. The most commonly prescribed medication for treating hypothyroidism is levothyroxine, while treatment for hyperthyroidism includes anti-thyroid medicines, such as propylthiouracil or methimazole, radioactive iodine which may destroy the thyroid gland and stop the excess production of thyroid hormones, even surgery to remove the thyroid gland altogether.

 

A dissatisfaction with normal care, however, has resulted in an increasing interest in a more holistic approach to thyroid disease treatment, one which prefers natural, lifestyle changes, not drugs or medications. Jen Wittman, CHHC, AADP, creator of Thyroid Loving Care and a certified holistic health expert, chef and writer, is an advocate of this strategy. Wittman was diagnosed with Hashimoto’s thyroid disease, an autoimmune disorder which attacks the thyroid gland itself, but was able to undo the illness without the use of medicines.

 

“In my experience, changing diet, improving gut health, managing stress and maintaining overall health and wellness helps support the body so that medicine is unnecessary, or at minimum, may work more effectively,” Wittman said.

 

Adopting a Healthy Diet

 

Wittman recommends eliminating gluten, caffeine and soy, in addition to reducing sugar for all thyroid diseases, however, she says that diets are contingent on the individual.

 

She clarified that some folks gain from a Paleo or Autoimmune Paleo protocol, while others will need to avoid foods like nightshades such as paprika, cayenne, tomatoes, bell peppers, eggplant and potatoes or polyunsaturated fatty acids such as peppermint and vegetable oils. Others also find cutting out milk or alcohol from their diet helps.

 

“There is not any effective one-size fits all approach when it comes to reversing autoimmune and thyroid conditions”.

 

According to Charlie Seltzer, MD, owner of Lean4Life Weight Loss & Fitness Solutions, another change some healthcare professionals suggest for individuals suffering from thyroid disease is to avoid eating raw goitrogenic foods like cruciferous vegetables, such as broccoli and kale, that interfere with the function of the thyroid gland.

 

But comments on diet’s influence on thyroid function have a tendency to vary. Jabbour, for example, doesn’t believe that exercise and diet can cure thyroid disorder. But one thing they could all agree on though is that eating healthier can fight weight gain and reduce a few of the symptoms like fatigue and depression, especially in the first six months of hormonal therapy when a balance of hormones has not yet been attained.

 

To Supplement or Not?

 

Too much or too little of certain nutrients can greatly impact thyroid function. Stella Lucia Volpe, PhD, RD, LDN, FACSM, professor and chair of the department of nutrition sciences at Drexel University at the College of Nursing & Health Professions, clarified that some thyroid diseases could be, but not necessarily is, a consequence of iodine deficiency. Iron or Zinc deficiencies can be variables as well. For instance, the thyroid converts iodine into thyroxin (T4) and triiodothyronine (T3) so a deficiency of iodine in your diet can interfere with hormone production.

 

But iodine deficiency is uncommon in the USA, Jabbour cautioned. Therefore supplementation could be harmful if no authentic deficiency is present, leading to the specific opposite problem. Too much iodine in your diet can also be an issue if you’re at risk for thyroid disease. Mario Skugor, MD, advises his patients with Graves’ disease, another autoimmune thyroid disease, because their thyroid is secreting a surplus of both T4 and T3 to prevent foods.

 

Wittman considers that most people with thyroid disorder need supplements at least short-term, but that they often can be weaned off them. “There is just not one simple way to reverse these conditions in everybody,” Wittman said. “Rather there are several unique supplements, lifestyle changes, healing modalities and dietary alterations which can be used to reverse the conditions and eliminate symptoms.” Seltzer cautioned against supplementing on your own. See your doctor and get appropriate testing first to make sure it’s necessary in the first location.

 

Exercise & Your Thyroid

 

Opinions on exercise also differ. Seltzer does not see it playing an important role in proper thyroid function while exercise in general is good for everybody. “The best exercise routine is the one that a individual is most likely to stay with,” Seltzer said. “I enjoy resistance training supplemented with cardiovascular exercise, with a focus on interval training, but if someone hates lifting weights, then anything is better than nothing.”

 

Wittman advises her clients to choose exercises which don’t tax the adrenal gland like gentle yoga, walking or Tai Chi. Jabbour and Skugor say patients with hyperthyroidism must watch the intensity and duration of the workouts because exercise may exacerbate an already rapid heart rate along with other symptoms.

 

What is the Best Strategy?

 

The absence of consensus on holistic approaches will likely cause your head to spin, right? Can you choose alternative remedies or would you rather stick with normal care for treating thyroid disease? The American Thyroid Association recommends that you work with your healthcare professional about the best strategies to include alternative or complementary medicine and always keep the lines of communication open if your doctor doesn’t approve of these practices. Your well-being is the priority, and a few inappropriate options, could interfere with your treatment.

 

The scope of our information is limited to chiropractic and spinal injuries and conditions. To discuss options on the subject matter, please feel free to ask Dr. Jimenez or contact us at 915-850-0900 .�
 

By Dr. Alex Jimenez

 

Additional Topics: Wellness

 

Overall health and wellness are essential towards maintaining the proper mental and physical balance in the body. From eating a balanced nutrition as well as exercising and participating in physical activities, to sleeping a healthy amount of time on a regular basis, following the best health and wellness tips can ultimately help maintain overall well-being. Eating plenty of fruits and vegetables can go a long way towards helping people become healthy.

 

blog picture of cartoon paperboy big news

 

TRENDING TOPIC: EXTRA EXTRA: About Chiropractic

 

 

How Lifestyle Changes Can Improve Thyroid Disease | Wellness Clinic

How Lifestyle Changes Can Improve Thyroid Disease | Wellness Clinic

Any doctor can tell you that to handle thyroid disease, you need a suitable dose of thyroid hormone to replace what your body isn’t currently making on its own, or that you may need other forms of medications to control the excess. However, it may also be worthwhile to consider that making lifestyle changes can be just as significant as these.

 

How can lifestyle changes help with thyroid disease?

 

‘If you’re not feeling well, there is much to be gained from focusing on a wholesome diet, regular exercise, stress control, and more to help you feel your best with thyroid disease”, states David Borenstein, MD, an integrative medicine physician in New York City. “It is extremely important to have a lifestyle which controls stress and provides appropriate nutrition and fitness,” he added.

 

You might start by analyzing your daily diet to see whether any changes or swaps could be made.�More exercise is just another lifestyle change that could make a large difference in the way you feel. As with a change in your diet, ask your doctor and start exercise routines.�Yoga classes, along with tai committed or chi meditation, can decrease tension or anxiety, which can be important when you live with hypothyroidism.

 

 

If you’re not feeling well despite following your thyroid disease treatment regimen as recommended by a healthcare professional, try these lifestyle hints from experts and people living with thyroid disease.

 

Be Vigilant About Eating Vegetables

 

Vegetables are a necessary part of a healthy diet, but people with hypothyroidism, or any other thyroid disease at that, might want to avoid cruciferous vegetables, like turnips and cabbage, as they can block thyroid hormone generation.

 

However, Benjamin Snider, ND, a naturopathic doctor at Authentic Wellness Integrative Health Centre at Kitchener, Ontario, says that cruciferous vegetables offer you many health benefits, and you should just limit them in case you’ve got a serious iodine deficiency, as that is when they are most likely to influence thyroid function. Dr. Snider recommends steaming cruciferous vegetables, which may limit their harmful tendencies.

 

Eat a Clean, Balanced Diet Daily

 

Lorraine Williams, a volunteer for the British Thyroid Foundation and a blogger in Thyroid Hope, demands people to avoid eating any highly processed foods. “Learn to listen to your body and eat for good health,” she says. Janelle Flores, a hypothyroidism blogger in Adventures of a Thyroidless Girl, is also an advocate for “clean” eating (she’s also gluten-free). “I’ve discovered that eating healthy provides me the most energy and the best outcome,” she states.

 

Exercise Often but With Certain Limits

 

Flores emphasizes the value of daily exercise while also listening to your own body. “If I’m having a bad day, I give myself a rest,” she states. “However, I feel that I don’t have as many bad times when I focus on eating correctly.” With the appropriate dose of medication and routine exercise, my energy level is a lot higher, ” she says.

 

“Moderate exercise is quite good for you. Just don’t overdo it,” Borenstein illustrated. Overexertion can affect the body’s ability to convert inactive thyroid hormone (T4) to the active form (T3) by eliminating an iodine molecule,” he explains, and “when that procedure does not happen properly, it can cause thyroid disease symptoms.”

 

Be Careful With Supplements

 

“Use caution when considering nutritional supplements that claim to boost thyroid function. These nutritional supplements aren’t proven effective”, says Anne R. Cappola, MD, an associate professor at the Perelman School of Medicine at the University of Pennsylvania at Philadelphia. Some contain unregulated amounts of thyroid hormones, leading to unregulated levels of the thyroid hormones.

 

In addition, a few alternative medicine practitioners may recommend iodine nutritional supplements for thyroid disease, but the majority of people in the United States actually have adequate iodine levels (although pregnant women can be an exception). “Substantial amounts of iodine in nutritional supplements can cause a faster drop in thyroid function in people predisposed to thyroid insufficiency,” Dr. Cappola states. “These supplements should be avoided.”

 

Maintain a Healthy Body Weight

 

Carrying too many pounds may lead to insulin resistance, which affects hormone levels, according to Borenstein. Plus, people that are overweight need more thyroid gland hormones. Individuals with borderline thyroid function might observe improvements in thyroid function when they maintain a healthy weight or lose weight.

 

Another weight reduction benefit includes the reduced risk of thyroid cancer. According to the University of Maryland Medical Center, the most common form of hypothyroidism, Hashimoto’s thyroiditis, raises the danger of a sort of thyroid cancer called thyroid lymphoma. And a study published online at Medical Science Monitor in January 2015 found that the risk for thyroid cancer also increases among overweight and obese individuals.

 

Manage Stress With Yoga or Meditation

 

“Introducing stress management and mindfulness techniques ought to be a component of any hypothyroid application,” Snider says. “That’s because stress weakens the immune system and also can raise the resistance of thyroid gland cells”, he says. Flores exercises to be physically fit, but also to lower stress. “I especially find jogging or running curative,” she states. However, when she is not feeling good, she allows herself to relax and indulge in a day. Borenstein recommends yoga, tai chi, and meditation to help alleviate stress.

 

Practice Restorative Sleep Habits Every Night

 

“Good sleep is a no-brainer,” Borenstein says. To repair tissues you will need sleep to help your body heal. “Sleep is critical in optimizing thyroid function because it helps to modulate the stress hormone cortisol,” Snider says. Stress management and exercise can enhance sleep quality, as can a normal sleep schedule and avoiding late-day caffeine, according to the National Sleep Foundation. Additionally, it is important to achieve a wholesome sleep environment.

 

Learn to Listen to Signals From Your Body

 

Thyroid disease is different for everybody, and everyone responds differently to treatment. “I have discovered my own body well enough to understand when I am feeling like when I need a drug dose shift,” Flores says. “Overall, medication is helpful because I need it to work effectively, but for me personally, I don’t think medication alone is the answer.”

 

Lee Parks, MD, an endocrinologist and also the clinical director of the Vanderbilt Thyroid Center at Vanderbilt University Medical Center in Nashville, Tennessee, says suitably treated hypothyroidism and other thyroid diseases shouldn’t result in weight gain, fatigue, or other common thyroid dysfunction symptoms. But lifestyle changes are just for fundamental good health, not a replacement for treatment, Dr. Parks concludes.

 

The scope of our information is limited to chiropractic and spinal injuries and conditions. To discuss options on the subject matter, please feel free to ask Dr. Jimenez or contact us at 915-850-0900 .�
 

By Dr. Alex Jimenez

 

Additional Topics: Wellness

 

Overall health and wellness are essential towards maintaining the proper mental and physical balance in the body. From eating a balanced nutrition as well as exercising and participating in physical activities, to sleeping a healthy amount of time on a regular basis, following the best health and wellness tips can ultimately help maintain overall well-being. Eating plenty of fruits and vegetables can go a long way towards helping people become healthy.

 

blog picture of cartoon paperboy big news

 

TRENDING TOPIC: EXTRA EXTRA: About Chiropractic

 

 

Metabolic Syndrome And Chiropractic

Metabolic Syndrome And Chiropractic

Metabolic Syndrome:

Key indexing terms:

  • Metabolic syndrome X
  • Insulin resistance
  • Hyperglycemia
  • Inflammation
  • Weight loss

Abstract
Objective: This article presents an overview of metabolic syndrome (MetS), which is a collection of risk factors that can lead to diabetes, stroke, and heart disease. The purposes of this article are to describe the current literature on the etiology and pathophysiology of insulin resistance as it relates to MetS and to suggest strategies for dietary and supplemental management in chiropractic practice.

Methods: The literature was searched in PubMed, Google Scholar, and the Web site of the American Heart Association, from the earliest date possible to May 2014. Review articles were identified that outlined pathophysiology of MetS and type 2 diabetes mellitus (T2DM) and relationships among diet, supplements, and glycemic regulation, MetS, T2DM, and musculoskeletal pain.

Results: Metabolic syndrome has been linked to increased risk of developing T2DM and cardiovascular disease and increased risk of stroke and myocardial infarction. Insulin resistance is linked to musculoskeletal complaints both through chronic inflammation and the effects of advanced glycosylation end products. Although diabetes and cardiovascular disease are the most well-known diseases that can result from MetS, an emerging body of evidence demonstrates that common musculoskeletal pain syndromes can be caused by MetS.

Conclusions: This article provides an overview of lifestyle management of MetS that can be undertaken by doctors of chiropractic by means of dietary modification and nutritional support to promote blood sugar regulation.

Introduction: Metabolic Syndrome

Metabolic syndrome (MetS) has been described as a cluster of physical examination and laboratory findings�that directly increases the risk of degenerative metabolic disease expression. Excess visceral adipose tissue, insulin resistance, dyslipidemia, and hypertension are conditions that significantly contribute to the syndrome. These conditions are united by a pathophysiological basis in low-grade chronic inflammation and increase an individual’s risk of cardiovascular disease, type 2 diabetes mellitus (T2DM), and all-cause mortality.1

The National Health and Nutrition Examination Survey (NHANES) 2003-2006 estimated that approximately 34% of United States adults aged 20 years and more had MetS.2 The same NHANES data found that 53% had abdominal adiposity, a condition that is closely linked to visceral adipose stores. Excess visceral adiposity generates increased systemic levels of pro-inflammatory mediator molecules. Chronic, low- grade inflammation has been well documented as an associated and potentially inciting factor for the development of insulin resistance and T2DM.1

NHANES 2003-2006 data showed that 39% of subjects met criteria for insulin resistance. Insulin resistance is a component of MetS that significantly contributes to the expression of chronic, low-grade inflammation and predicts T2DM expression. T2DM costs the United States in excess of $174 billion in 2007. 3 It is estimated that 1 in 4 adults will have T2DM by the year 2050.3 Currently, more than one third of US adults (34.9%) are obese, 4 and, in 2008, the annual medical cost of obesity was $147 billion.4,5 This clearly represents a health care concern.

The pervasiveness of MetS dictates that doctors of chiropractic will see a growing proportion of patients who fit the syndrome criteria.6 Chiropractic is most commonly used for musculoskeletal complaints believed to be mechanical in nature;6 however, an emerging body of evidence identifies MetS as a biochemical promoter of musculoskeletal complaints such as neck pain, shoulder pain, patella tendinopathy, and widespread musculoskeletal pain. 7�13 As an example, the cross-linking of collagen fibers can be caused by increased advanced glycation end-product (AGE) formation as seen in insulin resistance.14 Increased collagen cross-linking is observed in both osteoarthritis and degenerative disc disease, 15 and reduced mobility in elderly patients with T2DM has also been attributed to AGE-induced collagen cross-linking. 16,17

A diagnosis of MetS is made from a patient having 3 of the 5 findings presented in Table 1. Fasting hyperglycemia is termed impaired fasting glucose and indicates insulin resistance. 18,19 An elevated hemoglobin A1c (HbA1c) level measures long-term blood glucose�regulation and is diagnostic for T2DM when elevated in the presence of impaired fasting glucose. 3,18

metabolic table 1

The emerging evidence demonstrates that we cannot view musculoskeletal pain as only coming from conditions that are purely mechanical in nature. Doctors of chiropractic must demonstrate prowess in identification and management of MetS and an understanding of insulin resistance as its main pathophysiological feature. The purposes of this article are to describe the current literature on the etiology and pathophysiology of insulin resistance as it relates to MetS and to suggest strategies for dietary and supplemental management in chiropractic practice.

Methods

metabolic method arrowsPubMed was searched from the earliest possible date to May 2014 to identify review articles that outlined the pathophysiology of MetS and T2DM. This led to further search refinements to identify inflammatory mechanisms that occur in the pancreas, adipose tissue, skeletal muscle, and hypothalamus. Searches were also refined to identify relationships among diet, supplements, and glycemic regulation. Both animal and human studies were reviewed. The selection of specific supplements was based on those that were most commonly used in the clinical setting, namely, gymnema sylvestre, vanadium, chromium and ?-lipoic acid.

Discussion

Insulin Resistance Overview

metabolic insulin resistance 1Under normal conditions, skeletal muscle, hepatic, and adipose tissues require the action of insulin for cellular glucose entry. Insulin resistance represents an inability of insulin to signal glucose passage into insulin-dependent cells. Although a genetic predisposition can exist, the�etiology of insulin resistance has been linked to chronic low-grade inflammation.1 Combined with insulin resistance-induced hyperglycemia, chronic low-grade inflammation also sustains MetS pathophysiology.1

Two thirds of postprandial blood glucose metabolism occurs within skeletal muscle via an insulin-dependent mechanism.18,19 Insulin binding to its receptor triggers glucose entry and subsequently inhibits lipolysis within the target tissue.21,22 Glucose enters skeletal muscles cells by way of a glucose transporter designated Glut4. 18 Owing to genetic variability, insulin-mediated glucose uptake can vary more than 6-fold among non-diabetic individuals. 23

Prolonged insulin resistance leads to structural changes within skeletal muscle such as decreased Glut4 transporter number, intramyocellular fat accu- mulation, and a reduction in mitochondrial con- tent.19,24 These events are thought to impact energy generation and functioning of affected skeletal mus- cle.24 Insulin-resistant skeletal muscle is less able to suppress lipolysis in response to insulin binding.25 Subsequently, saturated free fatty acids accumulate and generate oxidative stress. 22 The same phenomenon within adipose tissue generates a rapid adipose cell expansion and tissue hypoxia.26 Both these processes increase inflammatory pathway activation and the generation of proinflammatory cytokines (PICs).27

Multiple inflammatory mediators are associated with the promotion of skeletal muscle insulin resistance. The PICs tumor necrosis factor ? (TNF-?), interleukin 1 (IL- 1), and IL-6 have received much attention because of their direct inhibition of insulin signaling.28�30 Since cytokine testing is not performed clinically, elevated levels of high- sensitivity C-reactive protein (hsCRP) best represent the low-grade systemic inflammation that characterizes insulin resistance.31,32

Insulin resistance�induced hyperglycemia can lead to irreversible changes in protein structure, termed glycation, and the formation of AGEs. Cells such as those of the vascular endothelium are most vulnerable to hyperglycemia due to utilization of an insulin-independent Glut1 transporter. 33 This makes AGE generation responsible for most diabetic complications, 15,33,34 including collagen cross-linking.15

If unchanged, prolonged insulin resistance can lead to T2DM expression. The relationship between chronic low-grade inflammation and T2DM has been well characterized. 35 Research has demonstrated that patients with T2DM also have chronic inflammation within the pancreas, termed insulitis, and it worsens hyperglycemia due to the progressive loss of insulin- producing ? cells.36�39

Visceral Adiposity And Insulin Resistance

metabolic Visceral Adiposity Insulin resistanceCaloric excess and a sedentary lifestyle contribute to the accumulation of subcutaneous and visceral adipose tissue. Adipose tissue was once thought of as a metabolically inert passive energy depot. A large body of evidence now demonstrates that excess visceral adipose tissue acts as a driver of chronic low-grade inflammation and insulin resistance.27,34

It has been documented that immune cells infiltrate rapidly expanding visceral adipose tissue. 26,40 Infil- trated macrophages become activated and release PICs that ultimately cause a phenotypic shift in resident macrophage phenotype to a classic inflammatory M1 profile.27 This vicious cycle creates a chronic inflam- matory response within adipose tissue and decreases the production of adipose-derived anti-inflammatory cytokines.43 As an example, adiponectin is an adipose- derived anti-inflammatory cytokine. Macrophage- invaded adipose tissue produces less adiponectin, and this has been correlated with increasing insulin resistance. 26

Hypothalamic Inflammation And Insulin Resistance

metabolic Hypothalamic Inflammation And Insulin ResistanceEating behavior in the obese and overweight has been popularly attributed to a lack of will power or genetics. However, recent research has demonstrated a link between hypothalamic inflammation and increased body weight.41,41

Centers that govern energy balance and glucose homeostasis are located within the hypothalamus. Recent studies demonstrate that inflammation in the hypothalamus coincides with metabolic inflammation and an increase in appetite.43 These hypothalamic centers simultaneously become resistant to anorexigenic stimuli, leading to altered energy intake. It has been suggested that this provides a neuropathological basis for MetS and drives a progressive increase in body weight. 41

Central metabolic inflammation pathologically activates hypothalamic immune cells and disrupts central insulin and leptin signaling.41 Peripherally, this has been associated with dysregulated glucose homeostasis that also impairs pancreatic ? cell functioning.41,44 Hypothalamic inflammation contributes to hypertension through similar mechanisms, and it is thought that central inflammation parallels chronic low-grade systemic inflammation and insulin resistance.41�44

Clinical Correlates Diet-Induced Inflammation & Insulin Resistance

Fatty foodsFeeding generally leads to a short-term increase in both oxidative stress and inflammation. 41 Total�calories consumed, glycemic index, and fatty acid profile of a meal all influence the degree of postprandial inflammation. It is estimated that the average American consumes approximately 20% of calories from refined sugar, 20% from refined grains and flour, 15% to 20% from excessively fatty meat products, and 20% from refined seed/legume oils.45 This pattern of eating contains a macronutrient composition and glycemic index that promote hyperglycemia, hyperlipemia, and an acute postprandial inflammatory response. 46 Collectively referred to as postprandial dysmetabolism, this pro-inflammatory response can sustain levels of chronic low-grade inflammation that leads to excess body fat, coronary heart disease (CHD), insulin resistance, and T2DM.28,29,47

Recent evidence suggests that several MetS criteria may not sufficiently identify all individuals with postprandial dysmetabolism. 48,49 A 2-hour oral glucose tolerance test (2-h OGTT) result greater than 200 mg/dL can be used clinically to diagnose T2DM. Although MetS includes a fasting blood glucose level less than 100 mg/dL, population studies have shown that a fasting glucose as low as 90 mg/dL can be associated with an 2-h OGTT level greater than 200 mg/dL.49 Further, a recent large cohort study indicated that an increased 2-h OGTT was independently predictive of cardiovascular and all-cause mortality in a nondiabetic population. 48 Mounting evidence indicates that post- prandial glucose levels are better correlated with MetS and predicting future cardiovascular events than fasting blood glucose alone.41,48

Fasting triglyceride levels generally correlate with postprandial levels, and a fasting triglyceride level greater than 150 mg/dL reflects MetS and insulin resistance. Contrastingly, epidemiologic data indicate that a fasting triglyceride level greater than 100 mg/dL influences CHD risk via postprandial dysmetabolism. 48 The acute postprandial inflammatory response that contributes to CHD risk includes an increase in PICs, free radicals, and hsCRP.48,49 These levels are not measured clinically but, monitoring fasting glucose, 2-hour postprandial glucose and fasting triglycerides can be used as correlates of postprandial dysmetabolic and low-grade systemic inflammation.

MetS And Disease Expression

metabolic diabetes related wordsDiagnosis of MetS has been linked to an increased risk of developing T2DM and cardiovascular disease over the following 5 to 10 years. 1 It further increases a patient’s risk of stroke, myocardial infarction, and death from any of the aforementioned conditions.1

Facchini et al47 followed 208 apparently healthy, non-obese subjects for 4 to 11 years while monitoring the incidence of clinical events such as hypertension, stroke, CHD, cancer, and T2DM. Approximately one fifth of participants experienced clinical events, and all of these subjects were either classified as intermediately or severely insulin resistant. It is important to note that all of these clinical events have a pathological basis in chronic low-grade inflammation,50 and no events were experienced in the insulin-sensitive groupings. 47

Insulin resistance is linked to musculoskeletal com- plaints both through chronic inflammation and the effects of AGEs. Advanced glycation end-products have been shown to extensively accumulate in osteoarthritic cartilage and treatment of human chondrocytes with AGEs increased their catabolic activity. 51 Advanced glycation end-products increase collagen stiffness via cross-linking and likely contribute to reduced joint mobility seen in elderly patients with T2DM.52 Com- pared to non-diabetics, type II diabetic patients are known to have altered proteoglycan metabolism in their intervertebral discs. This altered metabolism may pro- mote weakening of the annular fibers and subsequently, disc herniation.53 The presence of T2DM increases a person’s risk of expressing disc herniation in both the cervical and lumbar spines.17,54 Patients with T2DM are also more likely to develop lumbar stenosis compared with non-diabetics, and this has been documented as a plausible relationship between MetS risk factors and physician-diagnosed lumbar disc herniation. 55�57

There are no specific symptoms that denote early skeletal muscle structural changes. Fatty infiltration and decreased muscle mitochondria content are observed within age-related sarcopenia 58 ; however, it is still being argued whether fatty infiltration is a risk factor for low back pain. 59,60

Clinical management of MetS should be geared toward improving insulin sensitivity and reducing chronic low-grade inflammation. 1 Regular exercise without weight loss is associated with reduced insulin resistance, and at least 30 minutes of aerobic activity and resistance training is recommended daily. 61,62 Although frequently considered preventative, exercise, dietary, and weight loss interventions should be considered alongside pharmacological management in those with MetS. 1

Data regarding the exact amount of weight loss needed to improve chronic inflammation are inconclusive. In overweight individuals without diagnosed MetS, a very-low-carbohydrate diet (b 10% calories from carbohydrate) has significantly reduced plasma inflammatory markers (TNF-?, hsCRP, and IL-6) with�as little as 6% reduction in body weight.63,64 Individuals who meet MetS criteria may require 10% to 20% body weight loss to reduce inflammatory markers. 65 Interestingly, the Mediterranean Diet has been shown to reduce markers of systemic inflammation independent of weight loss65 and was recommended in the American College of Cardiology and American Heart Association Adult Treatment Panel 4 guidelines.66

A growing body of research has examined the effects of the Spanish ketogenic Mediterranean diet, including olive oil, green vegetables and salads, fish as the primary protein, and moderate red wine consumption. In a sample of 22 patients, adoption of the Spanish ketogenic Mediterranean diet with 9 g of supplemental salmon oil on days when fish was not consumed has led to complete resolution of MetS.67 Significant reductions in markers of chronic systemic inflammation were seen in 31 patients following this diet for 12 weeks.68

A Paleolithic diet based on lean meat, fish, fruits, vegetables, root vegetables, eggs, and nuts has been described as more satiating per calorie than a diabetes diet in patients with T2DM.69 In a randomized crossover study, a Paleolithic diet resulted in lower mean HbA1c values, triglycerides, diastolic blood pressure, waist circumference, improved glucose tolerance, and higher high-density lipoprotein (HDL) values compared to a diabetes diet.70 Within the context of these changes, a referral for medication management may be advisable.

Irrespective of name, a low-glycemic diet that focuses on vegetables, fruits, lean meats, omega-3 fish, nuts, and tubers can be considered anti-inflammatory and has been shown to ameliorate insulin resistance. 49,71�73 Inflammatory markers and insulin resistance further improve when weight loss coincides with adherence to an anti-inflammatory diet.70 A growing body of evidence suggests that specific supplemental nutrients also reduce insulin resistance and improve chronic low-grade inflammation.

Key Nutrients That Promote Insulin Sensitivity

metabolic nutrientsResearch has identified nutrients that play key roles in promoting proper insulin sensitivity, including vitamin D, magnesium, omega-3 (n-3) fatty acids, curcumin, gymnema, vanadium, chromium, and ?-lipoic acid. It is possible to get adequate vitamin D from sun exposure and adequate amounts of magnesium and omega-3 fatty acids from food. Contrastingly, the therapeutic levels of chromium and ?-lipoic acid that affect insulin sensitivity and reduce�insulin resistance cannot be obtained in food and must be supplemented.

Vitamin D, Magnesium, Omega-3 Fatty Acids, & Curcumin

metabolic Vitamin D, Magnesium, Omega-3 Fatty Acids, CurcuminVitamin D, magnesium, and n-3 fatty acids have multiple functions, and generalized inflammation reduction is a common mechanism of action.74�80 Their supplemental use should be considered in the context of low-grade inflammation reduction and health promotion, rather than as a specific treatment for MetS or T2DM.

Evidence pertaining to the precise role of vitamin D in MetS and insulin resistance is inconclusive. Increas- ing dietary and supplemental vitamin D intake in young men and women may lower the risk of MetS and T2DM development,81 and a low serum vitamin D level has been associated with insulin resistance and T2DM expression. 82 Supplementation to improve low serum vitamin D (reference range, 32-100 ng/mL) is effective, but its impact on improving central glycemia and insulin sensitivity is conflicting. 83 Treating insulin resistance and MetS with vitamin D as a monotherapy appears to be unsuccessful. 82,83 Achieving normal vitamin D blood levels through adequate sun exposure and/or supplementation is advised for general health. 84�86

The average American diet commonly contains a low magnesium intake.80 Recent studies suggest that supple- mental magnesium can improve insulin sensitivity. 81,82 Taking 365 mg/d may be effective in reducing fasting glucose and raising HDL cholesterol in T2DM,83 as well as normomagnesemic, overweight, nondiabetics. 84

Diets high in the omega-6 fat linoleic acid have been associated with insulin resistance85 and higher levels of serum pro-inflammatory mediator markers including IL-6, IL-1?, TNF-?, and hsCRP.87 Supplementation to increase dietary omega-3 fatty acids at the expense of omega-6 fatty acids has been shown to improve insulin sensitivity. 88�90 Six months of omega-3 supplementation at 3 g/d with meals has been shown to reduce MetS markers including fasting triglycerides, HDL cholesterol, and an increase in anti-inflammatory adiponectin. 91

Curcumin is responsible for the yellow pigmentation of the spice turmeric. Its biological effects can be characterized as antidiabetic and antiobesity via down- regulating TNF-?, suppressing nuclear factor ?B activation, adipocytokine expression, and leptin level modulation,. 92�95 Curcumin has been reported to activate peroxisome proliferator-activated receptor-?, the nuclear target of the thiazolidinedione class of antidiabetic drugs,93 and it also protects hepatic and pancreatic cells. 92,93 Numerous studies have reported�weight loss, hsCRP reduction, and improved insulin sensitivity after curcumin supplementation.92�95

There is no established upper limit for curcumin, and doses of up to 12 g/d are safe and tolerable in humans. 96 A randomized, double-blinded, placebo- controlled trial (N = 240) showed a reduced progression of prediabetes to T2DM after 9 months of 1500 mg/d curcumin supplementation.97

Curcumin, 98 vitamin D, 84 magnesium, 91 and omega-3 fatty acids80 are advocated as daily supplements to promote general health. A growing body of evidence supports the views of Gymnema sylvestre, vanadium, chromium, and ?-lipoic acid should as therapeutic supplements to assist in glucose homeostasis.

G Sylvestre

metabolic Gymnema sylvestre medicinal herbGymnemic acids are the active component of the G sylvestre plant leaves. Gymnemic acids are the active component of the G sylvestre plant leaves. Studies evaluating G sylvestre’s effects on diabetes in humans have generally been of poor methodological quality. Experimental animal studies have found that gymnemic acids may decrease glucose uptake in the small intestine, inhibit gluconeogenesis, and reduce hepatic and skeletal muscle insulin resistance.99 Other animal studies suggest that gymnemic acids may have comparable efficacy in reducing blood sugar levels to the first-generation sulfonylurea, tolbutamide.100

Evidence from open-label trials suggests its use as a supplement to oral antidiabetic hypoglycemic agents. 96 One quarter of patients were able to discontinue their drug and maintain normal glucose levels on an ethanolic gymnema extract alone. Although the evidence to date suggests its use in humans and animals is safe and well tolerated, higher quality human studies are warranted.

Vanadyl Sulfate

metabolic Vanadyl SulfateVanadyl sulfate has been reported to prolong the events of insulin signaling and may actually improve insulin sensitivity.101 Limited data suggest that it inhibits gluconeogenesis, possibly ameliorating hepatic insulin resistance. 100,101 Uncontrolled clinical trials have reported improvements in insulin sensitivity using 50 to 300 mg daily for periods ranging from 3 to 6 weeks. 101�103 Contrastingly, a recent randomized, double-blind, placebo-controlled trial found that 50 mg of vanadyl sulfate twice daily for 4 weeks had no effect in individuals with impaired glucose tolerance. 104 Limited clinical and experimental data exist supporting the use of vanadyl sulfate to improve insulin resistance,�and further research is warranted regarding its safety and efficacy.

Chromium

metabolic ChromiumDiets high in refined sugar and flour are deficient in chromium (Cr) and lead to an increased urinary excretion of chromium. 105,106 The progression of MetS is not likely caused by a chromium deficiency, 107 and dosages that benefit glycemic regulation are not achievable through food. 106,108,109

A recent randomize, double-blind trial demonstrated that 1000 ?g Cr per day for 8 months improved insulin sensitivity by 10% in subjects with T2DM.110 Cefalu et al110 further suggested that these improvements might be more applicable to patients with a greater degree of insulin resistance, impaired fasting plasma glucose, and higher HbA1c values. Chromium’s mechanism of action for improving insulin sensitivity is through increased Glut4 translocation via prolonging insulin receptor signaling.109 Chromium has been well tolerated at 1000 ?g/d,105 and animal models using significantly more than 1000 ? Cr per day were not associated with toxicological consequences.109

?-Lipoic Acid

metabolic alpha-lipoic-acidHumans derive ?-lipoic acid through dietary means and from endogenous synthesis. 111 The foods richest in ?-lipoic acid are animal tissues with extensive metabolic activity such as animal heart, liver, and kidney, which are not consumed in large amounts in the typical American diet. 111 Supplemental amounts of ?-lipoic acid used in the treatment of T2DM (300-600 mg) are likely to be as much as 1000 times greater than the amounts that could be obtained from the diet.112

Lipoic acid synthase (LASY) appears to be the key enzyme involved in the generation of endogenous lipoic acid, and obese mice with diabetes have reduced LASY expression when compared with age-and sex- matched controls.111 In vitro studies to identify potential inhibitors of lipoic acid synthesis suggest a role for diet-induced hyperglycemia and the PIC TNF- ? in the down-regulation of LASY.113 The inflammatory basis of insulin resistance may therefore drive lowered levels of endogenous lipoic acid via reducing the activity of LASY.

?-Lipoic acid has been found to act as insulin mimetic via stimulating Glut4-mediated glucose trans- port in muscle cells. 110,114?-Lipoic acid is a lipophilic free radical scavenger and may affect glucose homeostasis through protecting the insulin receptor from damage114 and indirectly via decreasing nuclear factor ?B�mediated TNF-? and IL-1 production. 110 In�postmenopausal women with MetS (presence of at least 3 ATPIII clinical criteria) 4 g/d of a combined inositol and ?-lipoic acid supplement for 6 months significantly improved OGTT scores by 20% in two thirds of the subjects. 114 A recent randomized double-blinded placebo-controlled study showed that 300 mg/d ?- lipoic acid for 90 days significantly decreased HbA1c values in subjects with T2DM.115

Side effects to ?-lipoic acid supplementation as high as 1800 mg/d have largely been limited to nausea. 116 It may be best to take supplemental ?-lipoic acid on an empty stomach (1 hour before or 2 hours after eating) because food intake reportedly reduces its bioavailability.117 Clinicians should be aware that ?-lipoic acid supplementation might increase the risk of hypoglycemia in diabetic patients using insulin or oral antidiabetic agents.117

Limitations

metabolic limitations signThis is a narrative overview of the topic of MetS. A systematic review was not performed; therefore, there may be relevant information missing from this review. The contents of this overview focuses on the opinions of the authors, and therefore, others may disagree with our opinions or approaches to management. This overview is limited by the studies that have been published. To date, no studies have been published that identify the effectiveness of a combination of a dietary intervention, such as the Spanish ketogenic diet, and nutritional supplementation on the expression of the MetS. Similarly, this approach has not been studied in patients with musculoskeletal pain who also have the MetS. Consequently, the information presented in this article is speculative. Longitudinal studies are needed before any specific recommendations can be made for patients with musculoskeletal that may be influenced by the MetS.

Conclusion: Metabolic Syndrome

This overview suggests that MetS and type 2 diabetes are complex conditions, and their prevalence is expected to increase substantially in the coming years. Thus, it is important to identify if the MetS may be present in patients who are nonresponsive to manual care and to help predict who may not respond adequately.

We suggest that diet and exercise are essential to managing these conditions, which can be supported with key nutrients, such as vitamin D, magnesium, and�omega-3 fatty acids. We also suggest that curcumin, G sylvestre, vanadyl sulfate chromium, and ?-lipoic acid could be viewed as specific nutrients that may be taken during the process of restoring appropriate insulin sensitivity and signaling.

Chiropractic Care

 

David R. Seaman DC, MS,?, Adam D. Palombo DC

Professor, Department of Clinical Sciences, National University of Health Sciences, Pinellas Park, FL Private Chiropractic Practice, Newburyport, MA

Funding Sources and Conflicts of Interest

No funding sources were reported for this study. David Seaman is a paid consultant for Anabolic Laboratories, a manufacturer of nutritional products for health care professionals. Adam Palombo was sponsored and remunerated by Anabolic laboratories to speak at chiropractic conventions/meetings.

Blank
References:

1. Kaur J. A comprehensive review on metabolic syndrome.<br />
Cardiol Res Pract 2014:943162, dx.doi.org/10.1155/<br />
2014/943162.<br />
2. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic<br />
syndrome among US adults. Findings from the Third National<br />
Health and Nutrition Examination Survey. J Am Med Assoc<br />
2006;287:356�9.<br />
3. Boyle JP, Thompson TJ, Gregg EW, Barker LE, Williamson<br />
DF. Projection of the year 2050 burden of diabetes in the US<br />
adult population: dynamic modeling of incidence, mortality,<br />
and prediabetes prevalence. Popul Health Metr 2010;8:29,<br />
dx.doi.org/10.1186/1478-7954-8-29.<br />
4. [Internet]Centers for Disease Control and Prevention.<br />
Adult Obesity Facts. Atlanta: CDC; 2014. [Available from<br />www.cdc.gov/obesity/data/adult.html%5D.<br />
5. Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of<br />
childhood and adult obesity in the United States, 2011�2012.<br />
JAMA 2014;311(8):806�14.<br />
6. Riksman JS, Williamson OD, Walker BF. Delineating<br />
inflammatory and mechanical sub-types of low back pain: a<br />
pilot survey of fifty low back pain patients in a chiropractic<br />
setting. Chiropr Man Therap 2011;19(1):5, dx.doi.org/<br />
10.1186/2045-709X-19-5.<br />
7. Dobretsov M, Ghaleb AH, Romanovsky D, Pablo CS, Stimers<br />
JR. Impaired insulin signaling as a potential trigger of<br />
pain in diabetes and prediabetes. Int Anesthesiol Clin<br />
2007;45(2):95�105.<br />
8. Mantyselka P, Miettola J, Niskanen L, Kumpusalo E. Glucose<br />
regulation and chronic pain at multiple sites. Rheumatology<br />
2008;47(8):1235�8.<br />
9. M�ntyselk� P, Miettola J, Niskanen L, Kumpusalo E.<br />
Persistent pain at multiple sites�connection to glucose<br />
derangement. Diabetes Res Clin Pract 2009;84(2):e30�2.<br />
10. Mantyselka P, Kautianen H, Vanhala M. Prevalence of neck<br />
pain in subjects with metabolic syndrome�a cross-sectional<br />
population-based study. BMC Musculoskelet Disord 2010;11:<br />
171, dx.doi.org/10.1186/1471-2474-11-171.<br />
11. Rechardt M, Shiri R, Karppinen J, Jula A, Heli�vaara M,<br />
Viikari-Juntura E. Lifestyle and metabolic factors in relation<br />
to shoulder pain and rotator cuff tendinitis: a population-based<br />
study. BMC Musculoskelet Disord 2010;11:165.<br />
12. Gaida JE, Alfredson L, Kiss ZS, Wilson AM, Alfredson H,<br />
Cook JL. Dyslipidemia in Achilles tendinopathy is<br />
characteristic of insulin resistance. Med Sci Sports Exerc<br />
2009;41:1194�7.<br />
13. Malliaras P, Cook JL, Kent PM. Anthropometric risk factors<br />
for patellar tendon injury among volleyball players. Br J<br />
Sports Med 2007;41:259�63.<br />
14. Skrzynski S. DSC study of collagen in disc disease. J Biophys<br />
2009;2009:819635, dx.doi.org/10.1155/2009/819635.<br />
15. Luevano-Contreras C, Chapman-Novakofski K. Dietary<br />
advanced glycation end products and aging. Nutrients<br />
2010;2(12):1247�65 [2009;2009:819635].<br />
16. Abate M, Schiavone C, Pelotti P, Salini V. Limited joint<br />
mobility (LJM) in elderly subjects with type II diabetes<br />
mellitus. Arch Gerontol Geriatrics 2011;53:135�40.<br />
17. Sakellaridis N. The influence of diabetes mellitus on lumbar<br />
intervertebral disk herniation. Surg Neurol 2006;66:152�4.<br />
18. Shepherd PR, Kahn BB. Glucose transporters and insulin<br />
action: implications for insulin resistance and diabetes<br />
mellitus. New Eng J Med 1999;341(4):248�57.<br />
19. Abdul-Ghani MA, DeFronzo RA. Pathogenesis of insulin<br />
resistance in skeletal muscle. J Biomed Biotechnol 2010:19,<br />
dx.doi.org/10.1155/2010/476279 [Article ID 476279].<br />
20. [Internet]American Heart Association. About metabolic<br />
syndrome. Dallas: The Association; 2014. [Available from<br />www.heart.org/HEARTORG/Conditions/More/<br />MetabolicSyndrome/About-Metabolic-Syndrome_UCM_<br />301920_Article.jsp].<br />
21. Hotamisligil GS. Inflammation and metabolic disorders.<br />
Nature 2006;444:860�7.<br />
22. Glass CK, Olefsky JM. Inflammation and lipid signaling in the<br />
etiology of insulin resistance. Cell Metab 2012;15(5):635�45.<br />
23. Reaven GM. All obese individuals are not created equal:<br />
insulin resistance is the major determinant of cardiovascular<br />
disease in overweight/obese individuals. Diabetes Vasc Dis<br />
Res 2005;2:105�12.<br />
24. Ritov VB, Menshikova EV, He J, Ferrell RE, Goodpaster<br />
BH, Kelley DE. Deficiency of subsarcolemmal mitochondria<br />
in obesity and type 2 diabetes. Diabetes 2005;54:8�14.<br />
25. Corcoran MP, Lamon-Fava S, Fielding RA. Trans fats and<br />
insulin resistance: skeletal muscle lipid deposition and insulin<br />
resistance: effect of dietary fatty acids and exercise. Am J Clin<br />
Nutr 2007;85:662�77.<br />
26. Schipper HS, Prakken B, Kalkhoven E, Boes M. Adipose<br />
tissue-resident immune cells: key players in immunometabolism.<br />
Trends Endocrinol Metab 2012;23:407�15.<br />
27. Antuna-Puente B, Feve B, Fellahi S, Bastard JP. Adipokines:<br />
the missing link between insulin resistance and obesity.<br />
Diabetes Metab 2008;34:2�11.<br />
28. Grimble RF. Inflammatory status and insulin resistance. Curr<br />
Opin Clin Nutr Metab Care 2003;5:551�9.<br />
29. Tilg H, Moschen AR. Inflammatory mechanisms in<br />
the regulation of insulin resistance. Mol Med 2008;3�4:222�31.<br />
30. Johnson DR, O’Conner JC, Satpathy A, Freund GG.<br />
Cytokines in type 2 diabetes. Vitam Horm 2006;74:405�41.<br />
31. Ridker PM, Wilson PW, Grundy SM. Should C-reactive<br />
protein be added to the metabolic syndrome and to<br />
assessment of global cardiovascular risk? Circulation 2004;<br />
109:2818�25.<br />
32. Gelaye B, Revilla L, Lopez T, et al. Association between<br />
insulin resistance and c-reactive protein among Peruvian<br />
adults. Diabetol Metab Syn 2010;2:30.<br />
33. Singh VP, Bali A, Singh N, et al. Advanced glycation end<br />
products and diabetic complications. Korean J Physiol<br />
Pharmacol 2014;18(1):1�14.<br />
34. Baker RG, Hayden MS. NF-kB, inflammation and metabolic<br />
disease. Cell Metab 2011;13(1):11�22.<br />
35. Purkayastha S, Cair D. Neuroinflammatory basis of metabolic<br />
syndrome. Mol Metab Nov 2013;2(4):356�63.<br />
36. Ehse JA, Boni-Schnetzler M, Faulenbach M, Donath MY.<br />
Macrophages, cytokines and beta-cell death in type 2 diabetes.<br />
Biochem Soc Trans 2008;36(3):340�2.<br />
37. Boni-Schnetzler M, Ehses JA, Faulenbach M, Donath MY.<br />
Insulitis in type 2 diabetes. Diabetes Obes Metab 2008;10<br />
(Suppl 4):201�4.<br />
38. Donath MY, Schumann DM, Faulenbach M, Ellingsgaard H,<br />
Perren A, Ehses JA. Islet inflammation in type 2<br />
diabetes: from metabolic stress to therapy. Diabetes Care<br />
2008;31(Suppl 2):S161�4.<br />
39. Donath MY, Boni-Schnetzler M, Ellingsgaard H, Ehses JA.<br />
Islet inflammation impairs the pancreatic beta-cell in type 2<br />
diabetes. Physiology 2009;24:325�31.<br />
40. Harford KA, Reynolds CM, McGillicuddy FC, Roche HM.<br />
Fats, inflammation and insulin resistance: insights to the role<br />
of macrophage and T-cell accumulation in adipose tissue.<br />
Proc Nutr Soc 2011;70:408�17.<br />
41. Munoz A, Costa M. Nutritionally mediated oxidative stress and<br />
inflammation. Oxid Med Cell Longev 2013;2013:610950, <br />
dx.doi.org/10.1155/2013/610950.<br />
42. Wisse BE, Schwartz MW. Does hypothalamic inflammation<br />
cause obesity? Cell Metab 2009;10(4):241�2.<br />
43. Purkayastha S, Cair D. Neuroinflammatory basis of metabolic<br />
syndrome. Mol Metab Nov 2013;2(4):356�63.<br />
44. Calegari VC, Torsoni AS, Vanzela EC, Ara�jo EP, Morari<br />
J, Zoppi CC, et al. Inflammation of the hypothalamus leads<br />
to defective pancreatic islet function. J Biol Chem 2011;<br />
286(15):12870�80.<br />
45. Cordain L, Eaton SB, Sebastian A, et al. Origins and evolution<br />
of the Western diet: health implications for the 21st century.<br />
Am J Clin Nutr 2005;81:341�54.<br />
46. Barclay AW, Petocz P, McMillan-Price J, et al. Glycemic<br />
index, glycemic load, and chronic disease risk�a metaanalysis<br />
of observational studies. Am J Clin Nutr<br />
2008;87:627�37.<br />
47. Facchini FS, Hua N, Abbasi F, Reaven GM. Insulin resistance<br />
as a predictor of age-related disease. J Clin Endocrinol Metab<br />
2001;86:3574�8.<br />
48. Lin H, Lee B, Ho Y, et al. Postprandial glucose improves the<br />
risk prediction of cardiovascular death beyond the metabolic<br />
syndrome in the nondiabetic population. Diabetes Care Sep<br />
2009;32(9):1721�6.<br />
49. O’Keefe JH, Bell DS. Postprandial hyperglycemia/<br />
hyperlipidemia (postprandial dysmetabolism) is a cardiovascular<br />
risk factor. Am J Cardiol 2007;100:899�904.<br />
50. Cao H. Adipocytokines in obesity and metabolic disease.<br />
J Endocrinol 2014;220(2):T47�59.<br />
51. Nah SS, Choi IY, Lee CK, et al. Effects of advanced glycation<br />
end products on the expression of COX2, PGE2 and NO in human osteoarthritic chondrocytes. Rheumatology (Oxford)<br />
2008;47(4):425�31.<br />
52. Abate M, Schiavone C, Pelotti P, Salini V. Limited joint<br />
mobility (LJM) in elderly subjects with type II diabetes<br />
mellitus. Arch Gerontol Geriatr 2011;53:135�40.<br />
53. Robinson D, Mirovsky Y, Halperin N, Evron Z, Nevo Z.<br />
Changes in proteoglycans of intervertebral disc in diabetic<br />
patients: a possible cause of increased back pain. Spine<br />
1998;23:849�56.<br />
54. Sakellaridis N, Androulis A. Influence of diabetes mellitus on<br />
cervical intervertebral disc herniation. Clin Neurol Neurosurg<br />
2008;110:810�2.<br />
55. Jhawar BS, Fuchs CS, Colditz GA, Stampfer MJ. Cardiovascular<br />
risk factors for physician-diagnosed lumbar disc<br />
herniation. Spine J 2006;6:684�91.<br />
56. Lotan R, Oron A, Anekstein Y, Shalmon E, Mirovsky Y.<br />
Lumbar stenosis and systemic diseases: is there any relevance.<br />
J Spinal Disord Tech 2008;21:247�51.<br />
57. Anekstein Y, Smorgick Y, Lotan R, et al. Diabetes mellitus as<br />
a risk factor for the development of lumbar spinal stenosis. Isr<br />
Med Assoc J 2010;12:16�20.<br />
58. Choi KM. Sarcopenia and sarcopenic obesity. Endocrinol<br />
Metab (Seoul) 2013;28(2):86�9.<br />
59. D’hooge R, Cagnie B, Crombez G, et al. Increased<br />
intramuscular fatty infiltration without differences in lumbar<br />
muscle cross-sectional area during remission of unilateral<br />
recurrent low back pain. Man Ther 2012 Dec;17(6):5584�8.<br />
60. Chen YY, Pao JL, Liaw CK, et al. Image changes of paraspinal<br />
muscles and clinical correlations in patients with unilateral<br />
lumbar spinal stenosis. Eur Spine J 2014;23(5):999�1006.<br />
61. Kim Y, Park H. Does regular exercise without weight loss<br />
reduce insulin resistance in children and adolescents? In J<br />
Endocrinol 2013:402592, dx.doi.org/10.1155/2013/<br />
402592 [Epub 2013 Dec 12].<br />
62. Strasser B, Siebert U, Schobersberger W. Resistance training<br />
in the treatment of the metabolic syndrome: a systematic<br />
review and meta-analysis of the effect of resistance training on<br />
metabolic clustering in patients with abnormal glucose<br />
metabolism. Sports Med 2010;40:397�415.<br />
63. Sharman MJ, Volek JS. Weight loss leads to reductions in<br />
inflammatory biomarkers after a very-low-carbohydrate diet<br />
and a low-fat diet in overweight men. Clin Sci (Lond)<br />
2004;13:365�9.<br />
64. Teng KT, Chang CY, Chang LF, et al. Modulation of obesityinduced<br />
inflammation by dietary fats: mechanisms and<br />
clinical evidence. Nutr J 2014;13:12, dx.doi.org/<br />
10.1186/1475-2891-13-12.<br />
65. Tzotzas T, Evangelou P, Kiortsis DN. Obesity, weight loss<br />
and conditional cardiovascular risk factors. Obes Rev 2011;12<br />
(5):e282�9.<br />
66. Stone N, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA<br />
Guideline on the Treatment of Blood Cholesterol to Reduce<br />
Atherosclerotic Cardiovascular Risk in Adults: A report of<br />
the American College of Cardiology/American Heart<br />
Association Task Force on practice guidelines. Circulation<br />
2014;129(25 Suppl 2):S1�S45.<br />
67. P�rez-Guisado J, Mu�oz-Serrano A. A pilot study of the<br />
Spanish ketogenic Mediterranean diet: an effective therapy for<br />
the metabolic syndrome. J Med Food 2011;14(7�8):681�7.<br />
68. P�rez-Guisado J, Mu�oz-Serrano A, Alonso-Moraga A.<br />
Spanish ketogenic Mediterranean diet: a healthy cardiovascular<br />
diet for weight loss. Nutr J 2008;7:30, dx.doi.org/<br />
10.1186/1475-2891-7-30.<br />
69. Jonsson T, Granfeldt Y, Lindeberg S, et al. Subjective satiety<br />
and other experiences of a Paleolithic diet compared to a<br />
diabetes diet in patients with T2DM. Nutr J 2013;12:105,<br />
dx.doi.org/10.1186/1475-2891-12-105.<br />
70. Jonsson T, Granfeldt Y, Ahren B, et al. Beneficial effects of a<br />
Paleolithic diet on cardiovascular risk factors in T2DM: a<br />
randomized cross-over pilot study. Cardiovasc Diabetol<br />
2009;8:35, dx.doi.org/10.1186/1475-2840-8-35.<br />
71. Nicklas BJ, You T, Pahor M. Behavioural treatments<br />
for chronic system inflammation: effects of dietary<br />
weight loss and exercise training. Can Med Assoc J<br />
2005;172(9):1199�209.<br />
72. O’Keefe JH, Gheewala NM, O’Keefe JO. Dietary<br />
strategies for improving post-prandial glucose, lipids, inflammation,<br />
and cardiovascular health. J Am Coll Cardiol<br />
2008;51:249�55.<br />
73. O’Keefe Jr JH, Cordain L. Cardiovascular disease resulting<br />
from a diet and lifestyle at odds with our Paleolithic genome:<br />
how to become a 21st-century hunter�gatherer. Mayo Clin<br />
Proc 2004;79(1):101�8.<br />
74. Ames BN. Low micronutrient intake may accelerate the<br />
degenerative diseases of aging through allocation of scarce<br />
micronutrients by triage. Proc Natl Acad Sci U S A 2006;103<br />
(47):17589�94.<br />
75. Holick MF, Chen TC. Vitamin D deficiency: a worldwide<br />
problem with health consequences. Am J Clin Nutr<br />
2008;87:1080S�6S [Suppl.].<br />
76. Toubi E, Shoenfeld Y. The role of vitamin D in regulating<br />
immune responses. Isr Med Assoc J 2010;12(3):174�5.<br />
77. King DE, Mainous AG, Geesey ME, Egan BM, Rehman S.<br />
Magnesium supplement intake and C-reactive protein levels<br />
in adults. Nutr Res 2006;26:193�6.<br />
78. Rosanoff A, Weaver CM, Rude RK. Suboptimal magnesium<br />
status in the United States: are the health consequences<br />
underestimated? Nutr Rev 2012;70(3):153�64.<br />
79. Simopoulos AP. Omega-3 fatty acids in inflammation and<br />
autoimmune diseases. J Am Coll Nutr 2002;21(6):495�505.<br />
80. Simopoulos AP. The importance of the omega-6/omega-3<br />
fatty acid ratio in cardiovascular disease and other chronic<br />
diseases. Exp Biol Med 2008;233:674�88.<br />
81. Fung GJ, Steffen LM, Zhou X, et al. Vitamin D intake is<br />
inversely related to risk of developing metabolic syndrome<br />
in African American and white men and women over 20 y:<br />
the Coronary Artery Risk Development in Young Adults<br />
study. Am J Clin Nutr 2012;96(1):24�9 [Published online<br />2012 May 30].<br />
82. Palomer X, Gonzalez-Clemente JM, Blanco-Vaca F, Mauricio<br />
D. Role of vitamin D in the pathogenesis of type 2 diabetes<br />
mellitus. Diabetes Obes Metab 2008;10:185�97.<br />
83. Guadarrama-Lopez AL, Valdes-Ramos R, Martinex-Carrillo<br />
BE. T2DM, PUFAs, and vitamin D: their relation to<br />
inflammation. J Immunol Res 2014;2014:860703, dx.<br />
doi.org/10.1155/2014/860703.<br />
84. Cannell JJ, Hollis BW. Use of vitamin D in clinical practice.<br />
Altern Med Rev 2008;13(1):6�20.<br />
85. Davidson MB, Duran P, Lee ML, Friedman TC. High-dose<br />
vitamin D supplementation in people with prediabetes and<br />
hypovitaminosis D. Diabetes Care 2013;36(2):260�6, <br />
dx.doi.org/10.2337/dc12-1204.<br />
86. Schwalfenberg G. Vitamin D, and diabetes: improvement of<br />
glycemic control with vitamin D3 repletion. Can Fam<br />
Physician 2008;54:864�6.<br />
87. Kim DJ, Xun P, Liu K, et al. Magnesium intake in relation to<br />
systemic inflammation, insulin resistance, and the incidence<br />
of diabetes. Diabetes Care 2010;33(12):2604�10, dx.<br />
doi.org/10.2337/dc10-0994.<br />
88. Guerrero-Romero F, Tamez-Perez HE, Gonz�lez-Gonz�lez G,<br />
et al. Oral magnesium supplementation improves insulin<br />
sensitivity in non-diabetic subjects with insulin resistance. A<br />
double-blind placebo-controlled randomized trial. Diabetes<br />
Metab 2004;30(3):253�8.<br />
89. Rodr�guez-Mor�n M, Guerrero-Romero F. Oral magnesium<br />
supplementation improves insulin sensitivity and metabolic<br />
control in type 2 diabetic subjects: a randomized double-blind<br />
controlled trial. Diabetes Care 2003;26(4):1147�52.<br />
90. Song Y, He K, Levitan EB, Manson JE, Liu S. Effects of oral<br />
magnesium supplementation on glycaemic control in type 2<br />
diabetes: a meta-analysis of randomized double-blind controlled<br />
trials. Diabet Med 2006;23(10):1050�6.<br />
91. Mooren FC, Kr�ger K, V�lker K, Golf SW,Wadepuhl M, Kraus<br />
A. Oral magnesium supplementation reduces insulin resistance<br />
in non-diabetic subjects�a double-blind, placebo-controlled,<br />
randomized trial. Diabetes Obes Metab 2011;13(3):281�4.<br />
92. Aggarwal BB. Targeting inflammation induced obesity and<br />
metabolic diseases by curcumin and other nutraceuticals.<br />
Annu Rev Nutr 2010;30:173�9.<br />
93. Alappat L, Awad AB. Curcumin and obesity: evidence and<br />
mechanisms. Nutr Rev 2010;68(12):729�38.<br />
94. Gonzales AM, Orlando RA. Curcumin and resveratrol inhibit<br />
nuclear factor-kappaB-mediated cytokine expression in adipocytes.<br />
Nutr Metab 2008;5:17, dx.doi.org/10.1186/<br />
1743-7075-5-17.<br />
95. Sahebkar A. Why it is necessary to translate curcumin into<br />
clinical practice for the prevention and treatment of metabolic<br />
syndrome? Biofactors 2012, dx.doi.org/10.1002/<br />
biof.1062 [Epub ahead of print].<br />
96. Hsu CH, Cheng AL. Clinical studies with curcumin. Adv Exp<br />
Med Biol 2007;595:471�80.<br />
97. Chuengsamarn S, Rattanamongkolgul S, Luechapudiporn R,<br />
Phisalaphong C, Jirawatnotai S. Curcumin extract for prevention<br />
of type 2 diabetes. Diabetes Care 2012;35(11):2121�7.<br />
98. Jurenka JS. Anti-inflammatory properties of curcumin, a<br />
major constituent of curcuma longa: a review of preclinical<br />
and clinical research. Altern Med Rev 2009;14(2):141�53.<br />
99. Leach M. Gymnema sylvestre for diabetes mellitus: a systematic<br />
review. J Altern Complement Med 2007;13(9):977�83.<br />
100. Chattopadhyay R. A comparative evaluation of some blood<br />
sugar lowering agents of plant origin. J Ethnopharmacol<br />
1999;67:367�72.<br />
101. Nahas R, Moher M. Complementary and alternative medicine<br />
for the treatment of type 2 diabetes. Can Fam Physician<br />
2009;55:591�6.<br />
102. Vanadium/Vanadyl sulfate: monograph. Altern Med Rev<br />
2009;14:17�80.<br />
103. Boden G, Chen X, Ruiz J, et al. Effects of vanadyl sulfate<br />
on carbohydrate and lipid metabolism in patients with noninsulin-dependent<br />
diabetes mellitus. Metabolism 1996;45:<br />
1130�5.<br />
104. Jacques-Camarena O, Gonz�lez-Ortiz M, Mart�nez-Abundis E,<br />
et al. Effect of vanadium on insulin sensitivity in patients with<br />
impaired glucose tolerance. Ann Nutr Metab 2008;53:195�8.<br />
105. Vincent JB. The biochemisty of chromium. J Nutr<br />
2000;130:715�8.<br />
106. Anderson RA. Chromium and insulin resistance. Nutr Res<br />
Rev 2003;16:267�75.<br />
107. Vincent JB. Chromium: celebrating 50 years as an essential<br />
element? Dalton Trans 2010;39:3787�94.<br />
108. Office of Dietary Supplements. [Internet]. Dietary supplement<br />
fact sheet: Chromium. Washington, DC: United States<br />
Department of Health and Human Services. ods.od.nih.<br />
gov/factsheets/chromium/. Reviewed November 4, 2013.<br />
109. Anderson RA. Chromium, glucose intolerance and diabetes.<br />
J Am Coll Nutr 1998;17(6):548�55.<br />
110. Cefalu WT, Rood J, Patricia Pinsonat P, et al. Characterization<br />
of the metabolic and physiologic response to chromium<br />
supplementation in subjects with type 2 diabetes mellitus.<br />
Metab Clin Exp 2010;59:755�62.<br />
111. Heimbach JT, Anderson RA. Chromium: recent studies regarding<br />
nutritional roles and safety. Nutr Today 2005;40(4):180�95.<br />
112. Shay KP, Moreau RF, Smith EJ, Smith AR, Hagen TM.<br />
Alpha-lipoic acid as a dietary supplement: molecular<br />
mechanisms and therapeutic potential. Biochim Biophys<br />
Acta 2009;1790:1149�60.<br />
113. Morikawa T, Yasuno R, Wada H. Do mammalian cells<br />
synthesize lipoic acid? Identification of a mouse cDNA<br />
encoding a lipoic acid synthase located in mitochondria.<br />
FEBS Lett 2001;498:16�21.<br />
114. Singh U, Jialal I. Alpha-lipoic acid supplementation and<br />
diabetes. Nutr Rev 2008;66(11):646�57.<br />
115. Padmalayam I, Hasham S, Saxena U, Pillarisetti S. Lipoic acid<br />
synthase (LASY): a novel role in inflammation, mitochondrial<br />
function, and insulin resistance. Diabetes 2009;58:600�8.<br />
116. Capasso I, Esposito E, Maurea N, et al. Combination of<br />
inositol and alpha lipoic acid in metabolic syndrome-affected<br />
women: a randomized placebo-controlled trial. Trial<br />
2013;14:273, dx.doi.org/10.1186/1745-6215-14-273.<br />
117. Udupa A, Nahar P, Shah S, et al. A comparative study of<br />
effects of omega-3 fatty acids, alpha lipoic acid and vitamin E<br />
in T2DM. Ann Med Health Sci Res 2013;3(3):442�6.

Close Accordion